Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12634617,area under the curve ratios,"The area under the curve ratios for RBC total to plasma lactone were 2.53+/-0.0640 and 2.13+/-0.442 in males and females, respectively.",Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12634617/),,2.53,492,DB01030,Topotecan
,12634617,area under the curve ratios,"The area under the curve ratios for RBC total to plasma lactone were 2.53+/-0.0640 and 2.13+/-0.442 in males and females, respectively.",Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12634617/),,2.13,493,DB01030,Topotecan
,8888741,MTD,"In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF.",Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888741/),[mg] / [m2],1.4,714,DB01030,Topotecan
,8888741,MTD,"In heavily pretreated children, the MTD for topotecan given by intermittent 30-min infusion for 5 days is 1.4 mg/m2 without GCSF and 2.0 mg/m2/day with GCSF.",Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8888741/),[mg] / [d·m2],2.0,715,DB01030,Topotecan
,19531625,area under the free carboplatin plasma concentration versus time curve,"Dose-limiting toxicities during the C-->T schedule were grade 4 thrombocytopenia and febrile neutropenia (MTD: carboplatin target area under the free carboplatin plasma concentration versus time curve, 4 min mg/mL; topotecan, 0.5 mg/m(2)/d).",Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531625/),[mg·min] / [ml],4,5613,DB01030,Topotecan
,19531625,area under the free carboplatin plasma concentration versus time curve,"Dose-limiting toxicities during the T-->C schedule included grade 4 neutropenia, thrombocytopenia, neutropenic fever, and grade 4 nausea and vomiting (MTD: carboplatin target area under the free carboplatin plasma concentration versus time curve, 6 min mg/mL; topotecan, 0.9 mg/m(2)/d).",Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531625/),[mg·min] / [ml],6,5614,DB01030,Topotecan
,26959658,optic nerve-to-plasma ratio,"The median optic nerve-to-plasma ratio after OAC and IV was 44 and 0.35, respectively.",Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26959658/),,44,9154,DB01030,Topotecan
,26959658,optic nerve-to-plasma ratio,"The median optic nerve-to-plasma ratio after OAC and IV was 44 and 0.35, respectively.",Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26959658/),,0.35,9155,DB01030,Topotecan
,1358575,clearance rate,"The clearance rate for topotecan lactone was 1220 ml/min/m2, with a range of 300-4760 ml/min/m2.",Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358575/),[ml] / [m2·min],1220,9483,DB01030,Topotecan
,1358575,clearance rate,"The clearance rate for total topotecan (lactone and hydroxy acid) was 493 ml/min/m2, with a range of 163-815 ml/min/m2.",Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358575/),[ml] / [m2·min],493,9484,DB01030,Topotecan
,1358575,clearance rate,The clearance rate for total topotecan in mice was 330 ml/min/m2 after administration of topotecan lactone.,Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1358575/),[ml] / [m2·min],330,9485,DB01030,Topotecan
,10100590,terminal half-life,CPT-lactone in plasma declined biexponentially with a terminal half-life of 102+/-25.2 min.,Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),min,102,15718,DB01030,Topotecan
,10100590,terminal half-life,The terminal half-life for TPT-lactone was 64.0+/-9.4 min.,Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),min,64.0,15719,DB01030,Topotecan
,10100590,brain,"The brain ECF to plasma distribution ratio was 0.38+/-0.12 for TPT-lactone, and 0.21+/-0.06 for TPT-carboxylate.",Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),,0.38,15720,DB01030,Topotecan
,10100590,brain,"The brain ECF to plasma distribution ratio was 0.38+/-0.12 for TPT-lactone, and 0.21+/-0.06 for TPT-carboxylate.",Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),,0.21,15721,DB01030,Topotecan
,10100590,ECF to plasma distribution ratio,"The brain ECF to plasma distribution ratio was 0.38+/-0.12 for TPT-lactone, and 0.21+/-0.06 for TPT-carboxylate.",Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),,0.38,15722,DB01030,Topotecan
,10100590,ECF to plasma distribution ratio,"The brain ECF to plasma distribution ratio was 0.38+/-0.12 for TPT-lactone, and 0.21+/-0.06 for TPT-carboxylate.",Comparative brain tissue distribution of camptothecin and topotecan in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10100590/),,0.21,15723,DB01030,Topotecan
,11489805,ne,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.12,16672,DB01030,Topotecan
,11489805,ne,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.11,16673,DB01030,Topotecan
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.12,16674,DB01030,Topotecan
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.11,16675,DB01030,Topotecan
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.09,16676,DB01030,Topotecan
,25677219,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) was 2.3 mg m(-2) day(-1) , given on days 1 to 5 in a 21 day cycle, for patients with prior PB chemotherapy or mild renal impairment, and 1.2 mg m(-2) day(-1) for patients with moderate renal impairment (suggested dose 1.9 mg m(-2) day(-1) for non-Asians).",Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677219/),[mg] / [(m)^2·day],2.3,18505,DB01030,Topotecan
,25677219,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) was 2.3 mg m(-2) day(-1) , given on days 1 to 5 in a 21 day cycle, for patients with prior PB chemotherapy or mild renal impairment, and 1.2 mg m(-2) day(-1) for patients with moderate renal impairment (suggested dose 1.9 mg m(-2) day(-1) for non-Asians).",Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677219/),[mg] / [(m)^2·day],1.2,18506,DB01030,Topotecan
,25677219,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) was 2.3 mg m(-2) day(-1) , given on days 1 to 5 in a 21 day cycle, for patients with prior PB chemotherapy or mild renal impairment, and 1.2 mg m(-2) day(-1) for patients with moderate renal impairment (suggested dose 1.9 mg m(-2) day(-1) for non-Asians).",Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677219/),[mg] / [(m)^2·day],1.9,18507,DB01030,Topotecan
≥,25677219,MTD,"Due to incomplete enrolment of patients with severe renal impairment, the MTD was determined as ≥ 0.6 mg m(-2) day(-1) in this cohort.",Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25677219/),[mg] / [(m)^2·day],0.6,18508,DB01030,Topotecan
,11221968,clearance,The topotecan lactone clearance determined after administration of topotecan alone and with hemodialysis was 5.3 l/h per m(2) vs 20.1 l/h per m2 respectively.,Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221968/),[h·l] / [m(2],5.3,22291,DB01030,Topotecan
,11221968,clearance,The topotecan lactone clearance determined after administration of topotecan alone and with hemodialysis was 5.3 l/h per m(2) vs 20.1 l/h per m2 respectively.,Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221968/),[l] / [h·m2],20.1,22292,DB01030,Topotecan
,11221968,plasma concentration,"At 30 min after the completion of hemodialysis, the topotecan plasma concentration obtained was greater than that measured at the end of hemodialysis (i.e. 8.0 ng/ml vs 4.9 ng/ml), suggesting a rebound effect.",Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221968/),ng,4.9,22293,DB01030,Topotecan
,11221968,terminal half-life,"The topotecan terminal half-life off dialysis was 13.6 h, compared with an apparent half-life determined during hemodialysis of 3.0 h.",Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221968/),h,13.6,22294,DB01030,Topotecan
,11221968,apparent half-life,"The topotecan terminal half-life off dialysis was 13.6 h, compared with an apparent half-life determined during hemodialysis of 3.0 h.",Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221968/),h,3.0,22295,DB01030,Topotecan
,15846298,terminal half-life,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),d,6.9-8.7,24736,DB01030,Topotecan
,15846298,steady-state volume of distribution,Pharmacokinetic studies in the mouse following intravenous injection showed that HGS-ETR1 serum concentrations were biphasic with a terminal half-life of 6.9-8.7 days and a steady-state volume of distribution of approximately 60 ml kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),[ml] / [kg],60,24737,DB01030,Topotecan
,15846298,Clearance,Clearance was 3.6-5.7 ml(-1) day(-1) kg(-1).,"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846298/),1/[day·kg·ml],3.6-5.7,24738,DB01030,Topotecan
,9400949,terminal half-life,Post-infusion total plasma levels of topotecan declined in a biphasic manner with a terminal half-life of 2.1 +/- 0.3 h.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),h,2.1,26220,DB01030,Topotecan
,9400949,Total body clearance,Total body clearance was 13.8 +/- 2.7 l h-1 m-2 with a steady-state volume of distribution of 36.7 +/- 6.2 l m-2.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[l] / [(m)^2·h],13.8,26221,DB01030,Topotecan
,9400949,steady-state volume of distribution,Total body clearance was 13.8 +/- 2.7 l h-1 m-2 with a steady-state volume of distribution of 36.7 +/- 6.2 l m-2.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[l] / [(m)^2],36.7,26222,DB01030,Topotecan
,9400949,maximal concentrations,"Mean maximal concentrations ranged from 0.23 to 0.53 nmol l-1, and were reached at 3.4 +/- 1.0 h after infusion.",Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[nM] / [l],0.23 to 0.53,26223,DB01030,Topotecan
,9400949,Maximal etoposide plasma concentrations,Maximal etoposide plasma concentrations of 0.75 +/- 0.54 and 1.23 +/- 0.57 micromol l-1 were reached at 2.4 +/- 1.2 and 2.3 +/- 1.0 h after ingestion of 20 and 40 mg respectively.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[μM] / [l],0.75,26224,DB01030,Topotecan
,9400949,Maximal etoposide plasma concentrations,Maximal etoposide plasma concentrations of 0.75 +/- 0.54 and 1.23 +/- 0.57 micromol l-1 were reached at 2.4 +/- 1.2 and 2.3 +/- 1.0 h after ingestion of 20 and 40 mg respectively.,Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9400949/),[μM] / [l],1.23,26225,DB01030,Topotecan
,32887301,bioavailability,"In addition, subcutaneous administration showed bioavailability from 88.05% (for lactone form) to 99.75% (for total form), and these values were four-five times greater than those of oral administration.",Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887301/),%,88.05,27466,DB01030,Topotecan
,32887301,bioavailability,"In addition, subcutaneous administration showed bioavailability from 88.05% (for lactone form) to 99.75% (for total form), and these values were four-five times greater than those of oral administration.",Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32887301/),%,99.75,27467,DB01030,Topotecan
,9607572,oral bioavailability,An oral bioavailability of TPT of 32-44% enables convenient prolonged administration.,Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607572/),%,32-44,27606,DB01030,Topotecan
,9607572,maximum tolerated dose,The maximum tolerated dose was 1.4 mg/m2/day.,Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607572/),[mg] / [d·m2],1.4,27607,DB01030,Topotecan
,9607572,maximum tolerated dose,The maximum tolerated dose was 0.7 mg/m2 b.i.d.,Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9607572/),[mg] / [m2],0.7,27608,DB01030,Topotecan
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,36.0,28079,DB01030,Topotecan
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,34.8,28080,DB01030,Topotecan
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,16.7,28081,DB01030,Topotecan
,25019569,objective response rates,"Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3).",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),%,0.0,28082,DB01030,Topotecan
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,7.4,28083,DB01030,Topotecan
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,7.1,28084,DB01030,Topotecan
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,3.5,28085,DB01030,Topotecan
,25019569,progression-free survival duration,"Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively.",A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25019569/),month,3.1,28086,DB01030,Topotecan
,19648970,progression-free survival,"Median progression-free survival and overall survival were 6.5 months and 2.7 years, respectively.",Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648970/),month,6.5,28837,DB01030,Topotecan
,19648970,overall survival,"Median progression-free survival and overall survival were 6.5 months and 2.7 years, respectively.",Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19648970/),years,2.7,28838,DB01030,Topotecan
,14990638,area under the plasma concentration-time curve,The maximum-tolerated dosage was 1.8 mg/m(2)/d; the mean (+/- standard deviation) area under the plasma concentration-time curve for topotecan lactone at this dosage was 20.9 +/- 8.4 ng/mL.,Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990638/),[ng] / [ml],20.9,31073,DB01030,Topotecan
,14990638,oral bioavailability,The population mean (+/- standard error) oral bioavailability of the injectable formulation was 0.27 +/- 0.03; that of capsules was 0.36 +/- 0.06 (P =.16).,Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990638/),,0.27,31074,DB01030,Topotecan
,14990638,oral bioavailability,The population mean (+/- standard error) oral bioavailability of the injectable formulation was 0.27 +/- 0.03; that of capsules was 0.36 +/- 0.06 (P =.16).,Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14990638/),,0.36,31075,DB01030,Topotecan
,11127941,CL,"A large interindividual variability was observed, with CL varying from 9.1 to 42.51 per hour (mean 21.0).",Population pharmacokinetics of topotecan: intraindividual variability in total drug. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11127941/),1/[h],21.0,32135,DB01030,Topotecan
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,2.3,33685,DB01030,Topotecan
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,5.6,33686,DB01030,Topotecan
,11571729,apparent steady-state plasma concentrations,"The mean values (+/- standard deviation) of the apparent steady-state plasma concentrations at the Phase II doses were 2.3 nM +/- 0.5 nM for topotecan lactone, 5.6 nM +/- 2.1 nM for total topotecan, and 40.1 nM +/- 16.8 nM for paclitaxel.",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),nM,40.1,33687,DB01030,Topotecan
,11571729,objective response rate,"There were seven partial responses (Phase II) contributing to an objective response rate of 28% and a median survival time of 11.7 months (range, 0.6-20.1 months).",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),%,28,33688,DB01030,Topotecan
,11571729,survival time,"There were seven partial responses (Phase II) contributing to an objective response rate of 28% and a median survival time of 11.7 months (range, 0.6-20.1 months).",A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571729/),month,11.7,33689,DB01030,Topotecan
,8708727,objective response rate,"Of 48 patients, none had a complete response and 19 had a partial response, for an objective response rate of 39% (95% confidence interval [CI], 25.2% to 53.0%).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),%,39,34898,DB01030,Topotecan
,8708727,response duration,"The median response duration was 4.8 months (95% CI, 3.0 to 7.3).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),month,4.8,34899,DB01030,Topotecan
,8708727,overall median survival time,"After a median follow-up duration of 18.2 months, the overall median survival time was 10.0 months (95% CI, 8.2 to 12.7); the 1-year survival rate was 39% (95% CI, 25.2% to 53.0%).",Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708727/),month,10.0,34900,DB01030,Topotecan
,11129727,apparent clearance,A significant difference (p=0.0082) of 38% was found between the apparent clearance of topotecan lactone after oral administration in males (237+/-105 l/h) and females (163+/-62.5 l/h).,Gender-dependent pharmacokinetics of topotecan in adult patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129727/),[l] / [h],237,43836,DB01030,Topotecan
,11129727,apparent clearance,A significant difference (p=0.0082) of 38% was found between the apparent clearance of topotecan lactone after oral administration in males (237+/-105 l/h) and females (163+/-62.5 l/h).,Gender-dependent pharmacokinetics of topotecan in adult patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11129727/),[l] / [h],163,43837,DB01030,Topotecan
,29138343,objective response rate,"The objective response rate was 10%, with 1 complete and 4 partial responses.",A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138343/),%,10,43952,DB01030,Topotecan
,1330081,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) of topotecan given in this schedule was 22.5 mg/m2.,A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330081/),[mg] / [m2],22.5,45495,DB01030,Topotecan
,1330081,total body clearance,The lactone was rapidly cleared from plasma with a total body clearance of 25.7 (+/- 6.7) l/h/m2.,A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330081/),[l] / [h·m2],25.7,45496,DB01030,Topotecan
,1330081,terminal half-life,The plasma lactone concentration declined rapidly with a harmonic mean terminal half-life of 3.4 (+/- 1.1)h.,A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1330081/),h,3.4,45497,DB01030,Topotecan
,9122851,plasma half-lives,"intravenous bolus, median plasma half-lives between 2 and 3 h.",[Topoisomerase I inhibitor with potential radiosensitizing effect]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122851/),h,2 and 3,53354,DB01030,Topotecan
,9122851,total-body clearance,and a total-body clearance of 0.57 l/min/m2 were seen.,[Topoisomerase I inhibitor with potential radiosensitizing effect]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122851/),[l] / [m2·min],0.57,53355,DB01030,Topotecan
,9122851,bioavailability,After oral administration the bioavailability varied between 30 and 35%.,[Topoisomerase I inhibitor with potential radiosensitizing effect]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122851/),%,30 and 35,53356,DB01030,Topotecan
,9060549,bioavailability,Recently bioavailability of an oral formulation of approximately 30% with limited variability was reported.,Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9060549/),%,30,53384,DB01030,Topotecan
,9060549,MTD,The MTD was 0.5 mg/m2 twice daily.,Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9060549/),[mg] / [m2],0.5,53385,DB01030,Topotecan
,19466380,half-life in brain,"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,1,54877,DB01030,Topotecan
,19466380,area under the concentration-time curve (AUC),"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),[d·μg] / [g],153.8,54878,DB01030,Topotecan
,19466380,area under the concentration-time curve (AUC),"At a dose of 10 microg (0.5 mg/ml), topoCED had a half-life in brain of approximately 1 day and increased the area under the concentration-time curve (AUC) by 28-fold over free topotecan (153.8 vs. 5.5 microg day/g).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),[d·μg] / [g],5.5,54879,DB01030,Topotecan
,19466380,50% inhibitory concentration (IC(50)),"In a U87MG cell assay, the 50% inhibitory concentration (IC(50)) of topoCED was approximately 0.8 microM at 48 and 72 h; its concentration-time curves were similar to free topotecan and unaffected by gadoCED.",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),μM,0.8,54880,DB01030,Topotecan
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,29.5,54881,DB01030,Topotecan
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,33.0,54882,DB01030,Topotecan
,19466380,overall survival,"In a U87MG intracranial rat xenograft model, a two-dose CED regimen of topoCED co-infused with gadoCED greatly increased median overall survival at dose levels of 0.5 mg/ml (29.5 days) and 1.0 mg/ml (33.0 days) vs. control (20.0 days; P < 0.0001 for both comparisons).",Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19466380/),d,20.0,54883,DB01030,Topotecan
,7689654,maximum tolerated dose,The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/m2 daily.,"Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7689654/),mg,1.,59108,DB01030,Topotecan
,7689654,maximum tolerated dose,The maximum tolerated dose for previously treated patients was 1.50 mg/m2 daily.,"Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7689654/),[mg] / [m2],1.50,59109,DB01030,Topotecan
,7689654,Plasma half-lives,"Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively.","Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7689654/),min,10,59110,DB01030,Topotecan
,7689654,Plasma half-lives,"Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively.","Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7689654/),min,100,59111,DB01030,Topotecan
,16001174,systemic clearances,"Median (range) irinotecan and topotecan lactone systemic clearances were 50.3 (16.6-76.2) l/h/m2 and 27.6 (14.7-55.9) l/h/m2, respectively.",Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001174/),[l] / [h·m2],50.3,68574,DB01030,Topotecan
,16001174,systemic clearances,"Median (range) irinotecan and topotecan lactone systemic clearances were 50.3 (16.6-76.2) l/h/m2 and 27.6 (14.7-55.9) l/h/m2, respectively.",Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16001174/),[l] / [h·m2],27.6,68575,DB01030,Topotecan
,20307538,C(max),"The C(max) vitreous/aqueous of treated eyes and the C(max) vitreous/plasma were approximately 8 and 254, respectively.",Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307538/),,8,70524,DB01030,Topotecan
,20307538,C(max),"The C(max) vitreous/aqueous of treated eyes and the C(max) vitreous/plasma were approximately 8 and 254, respectively.",Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20307538/),,254,70525,DB01030,Topotecan
,33860729,AUCs,"AUCs (h*ng/mL) for inhaled/IV topotecan in plasma, lung, liver, and brain were, 831/888, 60,000/1080, 8380/4000, and 297/15, respectively; while the half-life was also greatly increased in these tissues.",Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33860729/),[h·ng] / [ml],831/888,70770,DB01030,Topotecan
,33860729,AUCs,"AUCs (h*ng/mL) for inhaled/IV topotecan in plasma, lung, liver, and brain were, 831/888, 60,000/1080, 8380/4000, and 297/15, respectively; while the half-life was also greatly increased in these tissues.",Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33860729/),[h·ng] / [ml],"60,000/1080",70771,DB01030,Topotecan
,33860729,AUCs,"AUCs (h*ng/mL) for inhaled/IV topotecan in plasma, lung, liver, and brain were, 831/888, 60,000/1080, 8380/4000, and 297/15, respectively; while the half-life was also greatly increased in these tissues.",Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33860729/),[h·ng] / [ml],8380/4000,70772,DB01030,Topotecan
,33860729,AUCs,"AUCs (h*ng/mL) for inhaled/IV topotecan in plasma, lung, liver, and brain were, 831/888, 60,000/1080, 8380/4000, and 297/15, respectively; while the half-life was also greatly increased in these tissues.",Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33860729/),[h·ng] / [ml],297/15,70773,DB01030,Topotecan
,11839654,overall AUC,"In cycle 1, the daily dose for the last 2 days was dependent on the observed topotecan AUC at day 1; the general objective was to constrain the overall AUC (i.e., from day 1 to day 5) within 37,500-75,000 nM.min.",Individual adaptive dosing of topotecan in ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839654/),min·nM,"37,500-75,000",71028,DB01030,Topotecan
,11839654,observed AUC,"The dose adjustments allowed control of the topotecan exposure: mean (+/-SD) observed AUC of 70,697 (+/-12,364) nM.min.",Individual adaptive dosing of topotecan in ovarian cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839654/),min·nM,"70,697",71029,DB01030,Topotecan
,11839654,overall response rate,An overall response rate of 21% was observed in the 33 patients evaluable.,Individual adaptive dosing of topotecan in ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839654/),%,21,71030,DB01030,Topotecan
,8853931,volume of distribution (Vd) at steady-state,"Topotecan lactone is widely distributed into the peripheral space, with a mean volume of distribution (Vd) at steady-state of 75 L/m2.",Clinical pharmacokinetics of topotecan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8853931/),[l] / [m2],75,71825,DB01030,Topotecan
,8853931,total body clearance,"The mean total body clearance of the lactone form is 30 L/h/m2, with a mean elimination half-life (t1/2 beta) of 3 hours; renal clearance accounts for approximately 40% of the administered dose with a large interindividual variability.",Clinical pharmacokinetics of topotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8853931/),[l] / [h·m2],30,71826,DB01030,Topotecan
,8853931,elimination half-life (t1/2 beta),"The mean total body clearance of the lactone form is 30 L/h/m2, with a mean elimination half-life (t1/2 beta) of 3 hours; renal clearance accounts for approximately 40% of the administered dose with a large interindividual variability.",Clinical pharmacokinetics of topotecan. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8853931/),h,3,71827,DB01030,Topotecan
,8853931,oral bioavailablity,The oral bioavailablity of topotecan is approximately 35%.,Clinical pharmacokinetics of topotecan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8853931/),%,35,71828,DB01030,Topotecan
,9918204,bioavailability,An oral formulation of topotecan with a bioavailability of 32-44% in humans enables convenient prolonged administration.,A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918204/),%,32-44,72292,DB01030,Topotecan
,9918204,AUC(t),"At maximum-tolerated dose level, no significant difference in AUC(t) per course was found [AUC(t) per course was 107.4 +/- 33.7 ng x h/ml (o.d. x 5), 145.3 +/- 23.8 ng x h/ml (o.d. x 10), 100.0 +/- 41.5 ng x h/ml (b.i.d. x 10), and 164.9 +/- 92.2 ng x h/ml (b.i.d. x 21), respectively.]",A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918204/),[h·ng] / [ml],107.4,72293,DB01030,Topotecan
,9918204,AUC(t),"At maximum-tolerated dose level, no significant difference in AUC(t) per course was found [AUC(t) per course was 107.4 +/- 33.7 ng x h/ml (o.d. x 5), 145.3 +/- 23.8 ng x h/ml (o.d. x 10), 100.0 +/- 41.5 ng x h/ml (b.i.d. x 10), and 164.9 +/- 92.2 ng x h/ml (b.i.d. x 21), respectively.]",A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918204/),[h·ng] / [ml],145.3,72294,DB01030,Topotecan
,9918204,AUC(t),"At maximum-tolerated dose level, no significant difference in AUC(t) per course was found [AUC(t) per course was 107.4 +/- 33.7 ng x h/ml (o.d. x 5), 145.3 +/- 23.8 ng x h/ml (o.d. x 10), 100.0 +/- 41.5 ng x h/ml (b.i.d. x 10), and 164.9 +/- 92.2 ng x h/ml (b.i.d. x 21), respectively.]",A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918204/),[h·ng] / [ml],100.0,72295,DB01030,Topotecan
,9918204,AUC(t),"At maximum-tolerated dose level, no significant difference in AUC(t) per course was found [AUC(t) per course was 107.4 +/- 33.7 ng x h/ml (o.d. x 5), 145.3 +/- 23.8 ng x h/ml (o.d. x 10), 100.0 +/- 41.5 ng x h/ml (b.i.d. x 10), and 164.9 +/- 92.2 ng x h/ml (b.i.d. x 21), respectively.]",A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9918204/),[h·ng] / [ml],164.9,72296,DB01030,Topotecan
,15073866,maximum tolerated dose,The median maximum tolerated dose was 0.9 mg/m(2) per day (n = 19).,Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073866/),[mg] / [d·m(2)],0.9,72409,DB01030,Topotecan
,15073866,maximum total plasma topotecan concentration,"The calculated maximum total plasma topotecan concentration was 3.8 ng/mL (n = 7), with an area under the concentration-time curve of 38.4 ng.",Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073866/),[ng] / [ml],3.8,72410,DB01030,Topotecan
,15073866,area under the concentration-time curve,"The calculated maximum total plasma topotecan concentration was 3.8 ng/mL (n = 7), with an area under the concentration-time curve of 38.4 ng.",Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073866/),ng,38.4,72411,DB01030,Topotecan
,15073866,half-life,"hours/mL and a half-life of 4.1 hours, which would result in the complete disappearance of topotecan from the plasma after 12 hours.",Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073866/),h,4.1,72412,DB01030,Topotecan
,9848578,maximum tolerated dose,The maximum tolerated dose was 4 mg/m2 and acute dose-limiting toxicity was neutropenia.,Phase I and pharmacokinetic study of intraperitoneal topotecan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),[mg] / [m2],4,75563,DB01030,Topotecan
,9848578,k1,"Pharmacokinetic analysis performed at a dose of 3 mg/m2 demonstrated that elimination from the peritoneal cavity followed second-order kinetics with k1 = 1.6 hr(-1), k2 = 0.3 hr(-1) and first and second-phase half-lives of 0.49 and 2.7 hours, respectively.",Phase I and pharmacokinetic study of intraperitoneal topotecan. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),1/[hr],1.6,75564,DB01030,Topotecan
,9848578,k2,"Pharmacokinetic analysis performed at a dose of 3 mg/m2 demonstrated that elimination from the peritoneal cavity followed second-order kinetics with k1 = 1.6 hr(-1), k2 = 0.3 hr(-1) and first and second-phase half-lives of 0.49 and 2.7 hours, respectively.",Phase I and pharmacokinetic study of intraperitoneal topotecan. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),1/[hr],0.3,75565,DB01030,Topotecan
,9848578,first,"Pharmacokinetic analysis performed at a dose of 3 mg/m2 demonstrated that elimination from the peritoneal cavity followed second-order kinetics with k1 = 1.6 hr(-1), k2 = 0.3 hr(-1) and first and second-phase half-lives of 0.49 and 2.7 hours, respectively.",Phase I and pharmacokinetic study of intraperitoneal topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),h,0.49,75566,DB01030,Topotecan
,9848578,second-phase half-lives,"Pharmacokinetic analysis performed at a dose of 3 mg/m2 demonstrated that elimination from the peritoneal cavity followed second-order kinetics with k1 = 1.6 hr(-1), k2 = 0.3 hr(-1) and first and second-phase half-lives of 0.49 and 2.7 hours, respectively.",Phase I and pharmacokinetic study of intraperitoneal topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),h,2.7,75567,DB01030,Topotecan
,9848578,k,Plasma pharmacokinetic behavior was best described by first-order kinetics with k = 0.5 hr(-1) and a half-life of 3.9 hours.,Phase I and pharmacokinetic study of intraperitoneal topotecan. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),1/[hr],0.5,75568,DB01030,Topotecan
,9848578,half-life,Plasma pharmacokinetic behavior was best described by first-order kinetics with k = 0.5 hr(-1) and a half-life of 3.9 hours.,Phase I and pharmacokinetic study of intraperitoneal topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),h,3.9,75569,DB01030,Topotecan
,9848578,peritoneal to plasma AUC ratio,"The pharmacologic advantage, expressed as the peritoneal to plasma AUC ratio was 31.2.",Phase I and pharmacokinetic study of intraperitoneal topotecan. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9848578/),,31.2,75570,DB01030,Topotecan
,10632325,Css,"Css in six patients with complete data were 1.44 +/- 0.50 and 2.13 +/- 0.83 ng/ml at 0.3 and 0.4 mg/m2/day, respectively.",Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632325/),[ng] / [ml],1.44,78655,DB01030,Topotecan
,10632325,Css,"Css in six patients with complete data were 1.44 +/- 0.50 and 2.13 +/- 0.83 ng/ml at 0.3 and 0.4 mg/m2/day, respectively.",Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10632325/),[ng] / [ml],2.13,78656,DB01030,Topotecan
,7574810,alpha,"The plasma level of SK & F 104864 (lactone form) decreased bi-exponentially with mean alpha and beta half-lives of 0.101 h and 0.849 h at 2 mg/kg, respectively, and 0.518 h and 7.57 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.101,80688,DB01030,Topotecan
,7574810,alpha,"The plasma level of SK & F 104864 (lactone form) decreased bi-exponentially with mean alpha and beta half-lives of 0.101 h and 0.849 h at 2 mg/kg, respectively, and 0.518 h and 7.57 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.518,80689,DB01030,Topotecan
,7574810,beta half-lives,"The plasma level of SK & F 104864 (lactone form) decreased bi-exponentially with mean alpha and beta half-lives of 0.101 h and 0.849 h at 2 mg/kg, respectively, and 0.518 h and 7.57 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.849,80690,DB01030,Topotecan
,7574810,beta half-lives,"The plasma level of SK & F 104864 (lactone form) decreased bi-exponentially with mean alpha and beta half-lives of 0.101 h and 0.849 h at 2 mg/kg, respectively, and 0.518 h and 7.57 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,7.57,80691,DB01030,Topotecan
,7574810,AUCs,The AUCs were 0.846 micrograms.h/ml at 2 mg/kg and 2.14 micrograms.h/ml at 5 mg/kg.,[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],0.846,80692,DB01030,Topotecan
,7574810,AUCs,The AUCs were 0.846 micrograms.h/ml at 2 mg/kg and 2.14 micrograms.h/ml at 5 mg/kg.,[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],2.14,80693,DB01030,Topotecan
,7574810,alpha,"The plasma level of total topotecan (SK & F 104864 plus SK & F 105992) decreased bi-exponentially with mean alpha and beta half-lives of 0.696 h and 9.07 h at 2 mg/kg, respectively, and 0.795 h and 8.97 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.696,80694,DB01030,Topotecan
,7574810,alpha,"The plasma level of total topotecan (SK & F 104864 plus SK & F 105992) decreased bi-exponentially with mean alpha and beta half-lives of 0.696 h and 9.07 h at 2 mg/kg, respectively, and 0.795 h and 8.97 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.795,80695,DB01030,Topotecan
,7574810,beta half-lives,"The plasma level of total topotecan (SK & F 104864 plus SK & F 105992) decreased bi-exponentially with mean alpha and beta half-lives of 0.696 h and 9.07 h at 2 mg/kg, respectively, and 0.795 h and 8.97 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,9.07,80696,DB01030,Topotecan
,7574810,beta half-lives,"The plasma level of total topotecan (SK & F 104864 plus SK & F 105992) decreased bi-exponentially with mean alpha and beta half-lives of 0.696 h and 9.07 h at 2 mg/kg, respectively, and 0.795 h and 8.97 h at 5 mg/kg, respectively.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,8.97,80697,DB01030,Topotecan
,7574810,AUCs,The AUCs were 2.15 micrograms.h/ml at 2 mg/kg and 5.73 micrograms.h/ml at 5 mg/kg.,[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],2.15,80698,DB01030,Topotecan
,7574810,AUCs,The AUCs were 2.15 micrograms.h/ml at 2 mg/kg and 5.73 micrograms.h/ml at 5 mg/kg.,[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],5.73,80699,DB01030,Topotecan
,7574810,alpha,"After intravenous bolus injection of SK & F 104864 at 20 mg/kg into Sarcoma 180 bearing mice, the alpha and beta half-lives of SK & F 104864 were 0.401 h and 3.99 h, respectively, and the AUC was 5.49 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.401,80700,DB01030,Topotecan
,7574810,beta half-lives,"After intravenous bolus injection of SK & F 104864 at 20 mg/kg into Sarcoma 180 bearing mice, the alpha and beta half-lives of SK & F 104864 were 0.401 h and 3.99 h, respectively, and the AUC was 5.49 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,3.99,80701,DB01030,Topotecan
,7574810,AUC,"After intravenous bolus injection of SK & F 104864 at 20 mg/kg into Sarcoma 180 bearing mice, the alpha and beta half-lives of SK & F 104864 were 0.401 h and 3.99 h, respectively, and the AUC was 5.49 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],5.49,80702,DB01030,Topotecan
,7574810,alpha,"The alpha and beta half-lives of total topotecan were 0.517 h and 4.27 h, respectively, and the AUC was 9.88 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,0.517,80703,DB01030,Topotecan
,7574810,beta half-lives,"The alpha and beta half-lives of total topotecan were 0.517 h and 4.27 h, respectively, and the AUC was 9.88 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),h,4.27,80704,DB01030,Topotecan
,7574810,AUC,"The alpha and beta half-lives of total topotecan were 0.517 h and 4.27 h, respectively, and the AUC was 9.88 micrograms.hr/ml.",[Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574810/),[h·μg] / [ml],9.88,80705,DB01030,Topotecan
,22658903,AUC,"Under the proposed approach, the topotecan dosing was selected so as to achieve the final AUC value of 140±20 ng/ml h.",Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22658903/),[ng] / [h·ml],140,81265,DB01030,Topotecan
,9122737,volume of distribution,"Following intravenous administration for 5 days at doses of 0.5 to 1.5 mg/m2/d as a 30-minute infusion, topotecan has a volume of distribution of approximately 130 L.",An overview of the clinical pharmacology of topotecan. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122737/),l,130,81600,DB01030,Topotecan
,9122737,plasma clearance,"Mean plasma clearance for topotecan (total) was approximately 1,000 mL/min with a plasma half-life of 2 to 3 hours.",An overview of the clinical pharmacology of topotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122737/),[ml] / [min],"1,000",81601,DB01030,Topotecan
,9122737,plasma half-life,"Mean plasma clearance for topotecan (total) was approximately 1,000 mL/min with a plasma half-life of 2 to 3 hours.",An overview of the clinical pharmacology of topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9122737/),h,2 to 3,81602,DB01030,Topotecan
,12506183,maximum-tolerated dose (MTD),The maximum-tolerated dose (MTD) was 0.4 mg.,Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12506183/),mg,0.4,81625,DB01030,Topotecan
,9358562,bioavailability,"The bioavailability of topotecan, calculated from oral topotecan data or from SK&F 105,992 data, was approximately 50%.",The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9358562/),%,50,81823,DB01030,Topotecan
>,11585754,tumor,"Under all of the conditions, ST1481 exhibited an impressive efficacy in terms of tumor growth inhibition (tumor volume inhibition percentage > 99%), log(10) cell kill, rate of complete responses (including ""cures""), and an improvement of the therapeutic index compared with topotecan (used as the reference drug).","Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11585754/),,99,83093,DB01030,Topotecan
,16284058,half-life,Pharmacokinetic analysis confirmed the prolonged half-life of UCN-01 of approximately 15 days.,Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284058/),d,15,85490,DB01030,Topotecan
,10926808,concentrations,Steady state plasma topotecan lactone concentrations were a median of 1.2 ng/ml (range 0.4-8.00 ng/ml) following the first week of infusion.,A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],1.2,86426,DB01030,Topotecan
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],4.6,86427,DB01030,Topotecan
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],2.0,86428,DB01030,Topotecan
,10926808,steady state plasma topotecan lactone concentrations,"Mean steady state plasma topotecan lactone concentrations after the first week of infusion were 4.6, 2.0, and 1.3 ng/ml for partial response, stable disease, and progressive disease, respectively.",A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10926808/),[ng] / [ml],1.3,86429,DB01030,Topotecan
,9849451,bioavailability,An oral formulation of topotecan is available with a bioavailability of 32-44% in humans.,"Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9849451/),%,32-44,87862,DB01030,Topotecan
,16166443,complete remission rate,The complete remission rate in a heavily pretreated population was 16% (33% at the highest three dose levels).,Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16166443/),%,16,88063,DB01030,Topotecan
,16166443,complete remission rate,The complete remission rate in a heavily pretreated population was 16% (33% at the highest three dose levels).,Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16166443/),%,33,88064,DB01030,Topotecan
,7931489,Css,TPT Css values ranged from 4.8 to 72.5 nmol/L.,Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931489/),[nM] / [l],4.8 to 72.5,90740,DB01030,Topotecan
,7931489,LD90,"Colony-forming assays showed that the TPT LD90 (dose that inhibits the growth of leukemia blast colonies by 90%) values for blasts varied from 6 to 22 nmol/L, a range that overlapped with TPT Css values.",Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7931489/),[nM] / [l],6 to 22,90741,DB01030,Topotecan
,15310781,area under the plasma concentration-time curve (AUC),Pharmacokinetic studies were conducted on day 1 to attain a topotecan lactone area under the plasma concentration-time curve (AUC) of 120 to 160 ng/mL.h.,Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15310781/),[ng] / [h·ml],120 to 160,90754,DB01030,Topotecan
,15342988,la,The median topotecan lactone clearance was 15.5 L/h/m off hemodialysis and 18.7 L/h/m on hemodialysis.,Topotecan disposition in an anephric child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342988/),[l] / [h·m],15.5,90799,DB01030,Topotecan
,15342988,la,The median topotecan lactone clearance was 15.5 L/h/m off hemodialysis and 18.7 L/h/m on hemodialysis.,Topotecan disposition in an anephric child. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342988/),[l] / [h·m],18.7,90800,DB01030,Topotecan
,15342988,clearance,The median topotecan lactone clearance was 15.5 L/h/m off hemodialysis and 18.7 L/h/m on hemodialysis.,Topotecan disposition in an anephric child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342988/),[l] / [h·m],15.5,90801,DB01030,Topotecan
,15342988,clearance,The median topotecan lactone clearance was 15.5 L/h/m off hemodialysis and 18.7 L/h/m on hemodialysis.,Topotecan disposition in an anephric child. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15342988/),[l] / [h·m],18.7,90802,DB01030,Topotecan
,18761148,lambda(max),"A new, simple, sensitive and specific reversed-phase high performance liquid chromatographic (HPLC) method using ultraviolet detection was developed and validated for the analysis of CPT-11 (lambda(max)=254 nm, 365 nm) and its major active metabolite, SN-38 (lambda(max)=380 nm) in rat plasma and bile.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),,254,94652,DB01030,Topotecan
,18761148,lambda(max),"A new, simple, sensitive and specific reversed-phase high performance liquid chromatographic (HPLC) method using ultraviolet detection was developed and validated for the analysis of CPT-11 (lambda(max)=254 nm, 365 nm) and its major active metabolite, SN-38 (lambda(max)=380 nm) in rat plasma and bile.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),nm,380,94653,DB01030,Topotecan
,18761148,flow rate,The chromatographic separation was achieved by gradient elution consisting of acetonitrile and water (pH 3.0 adjusted with 20% o-phosphoric acid) at a flow rate of 1.0 ml/min.,"Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),[ml] / [min],1.0,94654,DB01030,Topotecan
,18761148,Total run time,Total run time for each sample was 30 min.,"Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,30,94655,DB01030,Topotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,11.4,94656,DB01030,Topotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,13.4,94657,DB01030,Topotecan
,18761148,retention times,"All the analytes viz. topotecan, CPT-11, SN-38 were well separated with retention times of 11.4, 13.4 and 15.5 min, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),min,15.5,94658,DB01030,Topotecan
,18761148,percent extraction efficiency,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,97,94659,DB01030,Topotecan
,18761148,extraction recovery,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,70,94660,DB01030,Topotecan
,18761148,extraction recovery,"The percent extraction efficiency was approximately 97% for CPT-11 and SN-38 from plasma while extraction recovery of CPT-11 and SN-38 from bile was approximately 70% and approximately 60%, respectively.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,60,94661,DB01030,Topotecan
,18761148,absolute bioavailability,"In the present study, irinotecan showed an absolute bioavailability of 30% as calculated from the pharmacokinetic data.","Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761148/),%,30,94662,DB01030,Topotecan
,18261372,systemic clearance,"Coadministration of NOV markedly increased oral TPT AUC(0-720) and Cmax by 3- and 4.5-fold, respectively, and decreased systemic clearance of i.v. injected TPT (from 44.40+/-7.28 without NOV to 29.44+/-1.99 ml/min/kg with NOV).",Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261372/),[ml] / [kg·min],44.40,96115,DB01030,Topotecan
,18261372,systemic clearance,"Coadministration of NOV markedly increased oral TPT AUC(0-720) and Cmax by 3- and 4.5-fold, respectively, and decreased systemic clearance of i.v. injected TPT (from 44.40+/-7.28 without NOV to 29.44+/-1.99 ml/min/kg with NOV).",Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261372/),[ml] / [kg·min],29.44,96116,DB01030,Topotecan
,18261372,permeability,"The inclusion of NOV in perfusate significantly increased TPT permeability from 0.81+/-0.30 x10(-6) to 1.26+/-0.12 x10(-6) cm/s, while, the intestinal secretion of TPT was reduced by ~50% when NOV was included in perfusate.",Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261372/),[cm] / [s],0.81,96117,DB01030,Topotecan
,18261372,permeability,"The inclusion of NOV in perfusate significantly increased TPT permeability from 0.81+/-0.30 x10(-6) to 1.26+/-0.12 x10(-6) cm/s, while, the intestinal secretion of TPT was reduced by ~50% when NOV was included in perfusate.",Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261372/),[cm] / [s],1.26,96118,DB01030,Topotecan
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],238.8,103008,DB01030,Topotecan
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],109.9,103009,DB01030,Topotecan
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],1297.2,103010,DB01030,Topotecan
,9435165,area under the plasma concentration time curve,"The predominant effect of probenecid was to increase hydroxy acid area under the plasma concentration time curve after administration of topotecan lactone (238.8 vs. 109.9 ng.hr/ml alone, P < .05), or hydroxy acid (1297.2 vs. 355.0 ng.hr/ml alone, P < .05).",Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435165/),[h·ng] / [ml],355.0,103011,DB01030,Topotecan
,20107803,CSF/plasma ratio,"At 1.0 mg/m(2)/d, the median CSF/plasma ratio was 19.4% (range 15.1-59.1%).","Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20107803/),%,19.4,103792,DB01030,Topotecan
,20107803,total plasma topotecan,"The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83).","Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20107803/),[ng] / [ml],4.63,103793,DB01030,Topotecan
,20107803,total plasma topotecan,"The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83).","Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20107803/),[ng] / [ml],5.87,103794,DB01030,Topotecan
,20107803,total plasma topotecan,"The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02-3.83).","Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20107803/),[ng] / [ml],3.4,103795,DB01030,Topotecan
,20107803,AUC,"The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m(2)/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3.","Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20107803/),,3,103796,DB01030,Topotecan
,21063221,MTD,We determined the MTD of nifurtimox to be 30 mg/kg/d.,A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21063221/),[mg] / [d·kg],30,104220,DB01030,Topotecan
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],182,105342,DB01030,Topotecan
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],725,105343,DB01030,Topotecan
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],188,105344,DB01030,Topotecan
,12012141,area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)),The inter-individual variability was pronounced and the area under the plasma concentration-time curve from time zero to infinity (AUC(0-infinity)) of the total topotecan plasma concentration ranged from 182 nmol/l h to 725 nmol/l h for topotecan alone and from 188 nmol/l h to 574 nmol/l h for topotecan and amifostine.,No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],574,105345,DB01030,Topotecan
,12012141,AUC(0-infinity),"The geometric mean of AUC(0-infinity) values were 326 nmol/l h and 297 nmol/l h, respectively ( P=0.41).",No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],326,105346,DB01030,Topotecan
,12012141,AUC(0-infinity),"The geometric mean of AUC(0-infinity) values were 326 nmol/l h and 297 nmol/l h, respectively ( P=0.41).",No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12012141/),[nM] / [h·l],297,105347,DB01030,Topotecan
,16806573,Cmax,The mean Cmax of topotecan on day 2 in responders (22.9+/-3.6) was significantly higher than that in non-responders (10.9+/-0.4).,A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806573/),,22.9,107806,DB01030,Topotecan
,16806573,Cmax,The mean Cmax of topotecan on day 2 in responders (22.9+/-3.6) was significantly higher than that in non-responders (10.9+/-0.4).,A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16806573/),,10.9,107807,DB01030,Topotecan
,11720828,half-life of the terminal part of the curve,"From the saliva data, the half-life of the terminal part of the curve was 2.64 h, it was of the same order of magnitude as the topotecan elimination half-life determined from the plasma data, 3.18 h.",Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720828/),h,2.64,108094,DB01030,Topotecan
,11720828,elimination half-life,"From the saliva data, the half-life of the terminal part of the curve was 2.64 h, it was of the same order of magnitude as the topotecan elimination half-life determined from the plasma data, 3.18 h.",Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720828/),h,3.18,108095,DB01030,Topotecan
,11720828,S/P ratio,One patient with high salivary concentrations (mean S/P ratio=4.60) had grade 1 mucositis.,Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11720828/),,4.60,108096,DB01030,Topotecan
,18978345,maximum dose,"For this phase I study, a starting dose of 0.5 mg of periocular topotecan administered through a 25-gauge needle was given with intrapatient escalation at a rate of 0.5 mg/cycle according to toxicity, up to a maximum dose of 2 mg.",A phase I study of periocular topotecan in children with intraocular retinoblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978345/),,2,111084,DB01030,Topotecan
,18172284,area under the plasma concentration-time curve,"The topotecan dosage was individualized to attain a topotecan lactone area under the plasma concentration-time curve between 80 and 120 ng/mL h and given over a protracted schedule (i.e., 10 days).",Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18172284/),[ng] / [h·ml],80 and 120,117577,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),,18,118183,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),[l] / [(m)^2·h],16,118184,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),,29,118185,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),[l] / [(m)^2·h],28,118186,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),,16,118187,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),[l] / [(m)^2·h],10,118188,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),,7,118189,DB01030,Topotecan
,15838660,clearance,"However, the mean clearance for docetaxel (18 for all 16 L h(-1) m(-2) and 29 for all 28 L h(-1) m(-2) on schedules A and B, respectively, and topotecan 16 for all 10 L h(-1) m(-2) and 7 for all 6 L h(-1) m(-2) on schedules A and B, respectively) were not statistically different (P > 0.05).",Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838660/),[l] / [(m)^2·h],6,118190,DB01030,Topotecan
,11138457,time to progression,"One patient with extensively pretreated ovarian carcinoma had a partial response, and eight patients with various solid tumor malignancies had stable disease with a median time to progression of 12 weeks (range 9-18 weeks).",Phase I study of docetaxel and topotecan in patients with solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11138457/),weeks,12,119544,DB01030,Topotecan
,24074809,elimination half-life time (T1/2),The maximum plasma concentration (Cmax) reached at 1-2 h and the elimination half-life time (T1/2) was approximately 4.2 h after oral administration.,"Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24074809/),h,4.2,119951,DB01030,Topotecan
,24074809,absolute bioavailability,"The absolute bioavailability of total topotecan in the 1.5 mg/m(2)/d and 1.9 mg/m(2)/d groups averaged 41.23 ± 11.8% and 36.00 ± 14.8%, respectively.","Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24074809/),%,41.23,119952,DB01030,Topotecan
,24074809,absolute bioavailability,"The absolute bioavailability of total topotecan in the 1.5 mg/m(2)/d and 1.9 mg/m(2)/d groups averaged 41.23 ± 11.8% and 36.00 ± 14.8%, respectively.","Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24074809/),%,36.00,119953,DB01030,Topotecan
,20974678,response rate,"The response rate was 28.2% (95% confidence interval, 18.1-40.1%).",A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20974678/),%,28.2,121587,DB01030,Topotecan
,19174487,Cmax,"AG014699 metabolites distributed rapidly into the plasma (Cmax, 1.2-1.9 nmol/L at 30 min) and accumulated in xenograft tissues (Cmax, 1-2 micromol/L at 120 min), associated with a sustained suppression of PARP-1 enzyme activity.",Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19174487/),[nM] / [l],1.2-1.9,121726,DB01030,Topotecan
,19174487,Cmax,"AG014699 metabolites distributed rapidly into the plasma (Cmax, 1.2-1.9 nmol/L at 30 min) and accumulated in xenograft tissues (Cmax, 1-2 micromol/L at 120 min), associated with a sustained suppression of PARP-1 enzyme activity.",Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19174487/),[μM] / [l],1-2,121727,DB01030,Topotecan
,7767947,peak concentrations,"The mean peak concentrations of lactone and total drug in ventricular CSF were 83 +/- 18 microM and 88 +/- 25 microM, respectively.",Intrathecal administration of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),μM,83,122069,DB01030,Topotecan
,7767947,peak concentrations,"The mean peak concentrations of lactone and total drug in ventricular CSF were 83 +/- 18 microM and 88 +/- 25 microM, respectively.",Intrathecal administration of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),μM,88,122070,DB01030,Topotecan
,7767947,terminal half-life,CSF drug elimination of the lactone was bi-exponential with a terminal half-life of 1.3h.,Intrathecal administration of topotecan in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),h,1.3,122071,DB01030,Topotecan
,7767947,clearance from ventricular CSF,The mean clearance from ventricular CSF was 0.075 ml/min for the lactone and 0.043 ml/min for total drug.,Intrathecal administration of topotecan in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),[ml] / [min],0.075,122072,DB01030,Topotecan
,7767947,clearance from ventricular CSF,The mean clearance from ventricular CSF was 0.075 ml/min for the lactone and 0.043 ml/min for total drug.,Intrathecal administration of topotecan in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),[ml] / [min],0.043,122073,DB01030,Topotecan
,7767947,Peak lumbar concentrations,"Peak lumbar concentrations (n = 1), which occurred 2 h after intraventricular drug administration, were 0.98 microM and 2.95 microM for the lactone and total drug, respectively.",Intrathecal administration of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),μM,0.98,122074,DB01030,Topotecan
,7767947,Peak lumbar concentrations,"Peak lumbar concentrations (n = 1), which occurred 2 h after intraventricular drug administration, were 0.98 microM and 2.95 microM for the lactone and total drug, respectively.",Intrathecal administration of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7767947/),μM,2.95,122075,DB01030,Topotecan
,15956976,response rate (RR),The response rate (RR) was 28% in 18 evaluable patients.,Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15956976/),%,28,132862,DB01030,Topotecan
,11193899,elimination half-lives,Pharmacokinetic analysis demonstrates a second-order kinetics with elimination half-lives of 0.49 and 2.7 hours.,Alternative administration of camptothecin analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),h,0.49,133092,DB01030,Topotecan
,11193899,elimination half-lives,Pharmacokinetic analysis demonstrates a second-order kinetics with elimination half-lives of 0.49 and 2.7 hours.,Alternative administration of camptothecin analogues. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),h,2.7,133093,DB01030,Topotecan
,11193899,peritoneal to plasma AUC ratio,The peritoneal to plasma AUC ratio was 31.2.,Alternative administration of camptothecin analogues. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11193899/),,31.2,133094,DB01030,Topotecan
higher,12109520,maximum tolerated dose (MTD),"The dose-limiting factor (DLF) was reversible leucopenia, and the maximum tolerated dose (MTD) was higher than 22.5 mg/m2 in the single-dose study.",Phase I studies of nogitecan hydrochloride for Japanese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12109520/),[mg] / [m2],22.5,134413,DB01030,Topotecan
,12109520,MTD,"In the 5-day repeat-dose study, the DLF was also reversible leucopenia, and the MTD was estimated to be 1.5 mg/m2 per day.",Phase I studies of nogitecan hydrochloride for Japanese. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12109520/),[mg] / [d·m2],1.5,134414,DB01030,Topotecan
,12109520,half-life,"The plasma concentration of nogitecan hydrochloride increased with increasing dose, and the half-life after single dosing ranged from 3 to 5h.",Phase I studies of nogitecan hydrochloride for Japanese. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12109520/),h,3 to 5,134415,DB01030,Topotecan
,12576429,area under the plasma concentration time curve (AUC),Doses were individualized based on the patient's topotecan systemic clearance to attain a single day topotecan lactone area under the plasma concentration time curve (AUC) of 120-180 ng/ml x h (cohort 1) or 80-120 ng/ml x h (cohort 2).,A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576429/),[ng] / [h·ml],120-180,135754,DB01030,Topotecan
,12576429,area under the plasma concentration time curve (AUC),Doses were individualized based on the patient's topotecan systemic clearance to attain a single day topotecan lactone area under the plasma concentration time curve (AUC) of 120-180 ng/ml x h (cohort 1) or 80-120 ng/ml x h (cohort 2).,A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576429/),[ng] / [h·ml],80-120,135755,DB01030,Topotecan
,12576429,AUCs,"The median topotecan dosages required to achieve the target AUCs for cohorts 1 and 2 were 4 mg/m(2) (range, 2.6-6) and 3 mg/m(2) (range, 2.6-4.2), respectively.",A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576429/),[mg] / [m(2],4,135756,DB01030,Topotecan
,12576429,AUCs,"The median topotecan dosages required to achieve the target AUCs for cohorts 1 and 2 were 4 mg/m(2) (range, 2.6-6) and 3 mg/m(2) (range, 2.6-4.2), respectively.",A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12576429/),[mg] / [m],3,135757,DB01030,Topotecan
,33095287,maximum tolerated dose (MTD),"In Part D, the maximum tolerated dose (MTD) was exceeded at 165 mg/m2/dose of crizotinib cMS.","Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33095287/),mg,165,138074,DB01030,Topotecan
,17145877,brain ECF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.21,139485,DB01030,Topotecan
,17145877,brain ECF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.61,139486,DB01030,Topotecan
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.21,139487,DB01030,Topotecan
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.61,139488,DB01030,Topotecan
,17145877,CSF,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.18,139489,DB01030,Topotecan
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.18,139490,DB01030,Topotecan
,17145877,to plasma AUC ratio,"After 4 and 8 mg/kg topotecan i.v., the brain ECF to plasma AUC ratio of unbound topotecan lactone was 0.21 +/- 0.04 and 0.61 +/- 0.16, respectively; the ventricular CSF to plasma AUC ratio was 1.18 +/- 0.10 and 1.30 +/- 0.13, respectively.",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,1.30,139491,DB01030,Topotecan
,17145877,brain ECF to plasma AUC ratio,"The brain ECF to plasma AUC ratio of unbound topotecan lactone increased by 1.6-fold to 0.35 +/- 0.04, which was significantly different from the ratio without gefitinib (P < 0.05).",Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.35,139492,DB01030,Topotecan
,17145877,CSF to plasma AUC ratio,The ventricular CSF to plasma AUC ratio significantly decreased to 0.98 +/- 0.05 (P < 0.05).,Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145877/),,0.98,139493,DB01030,Topotecan
>,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,200,139631,DB01030,Topotecan
,15501959,time to blood neutrophils,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,28,139632,DB01030,Topotecan
>,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),,"20,000",139633,DB01030,Topotecan
,15501959,time to platelets,"Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days.","A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15501959/),d,40,139634,DB01030,Topotecan
,21104004,tissue-to-plasma partition coefficients,Mean tissue-to-plasma partition coefficients ranged from 0.123 (brain) to 55.3 (kidney).,Physiologically based pharmacokinetic model for topotecan in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21104004/),,0.123,140233,DB01030,Topotecan
,21104004,tissue-to-plasma partition coefficients,Mean tissue-to-plasma partition coefficients ranged from 0.123 (brain) to 55.3 (kidney).,Physiologically based pharmacokinetic model for topotecan in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21104004/),,55.3,140234,DB01030,Topotecan
,28156017,apparent clearance (CL/F),"The apparent clearance (CL/F) and volume (Vc /F) were 16.5 l h-1 and 122.7 l, respectively.",Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156017/),[l] / [h],16.5,143566,DB01030,Topotecan
,28156017,volume (Vc /F),"The apparent clearance (CL/F) and volume (Vc /F) were 16.5 l h-1 and 122.7 l, respectively.",Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28156017/),l,122.7,143567,DB01030,Topotecan
,8240998,maximal tolerated dose,The maximal tolerated dose was 1.5 mg/m2/day.,"Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240998/),[mg] / [d·m2],1.5,143926,DB01030,Topotecan
,8240998,t 1/2 (alpha),"Pharmacokinetics showed a t 1/2 (alpha) of 8.1 +/- 7.6 min., t 1/2 (beta) of 132 +/- 48 min., Vd,ss 72.7 +/- 26.9 L/m2 and Cltot of 0.57 +/- 0.16 L/min/m2.","Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240998/),min,8.1,143927,DB01030,Topotecan
,8240998,t 1/2 (beta),"Pharmacokinetics showed a t 1/2 (alpha) of 8.1 +/- 7.6 min., t 1/2 (beta) of 132 +/- 48 min., Vd,ss 72.7 +/- 26.9 L/m2 and Cltot of 0.57 +/- 0.16 L/min/m2.","Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240998/),min,132,143928,DB01030,Topotecan
,8240998,"Vd,ss","Pharmacokinetics showed a t 1/2 (alpha) of 8.1 +/- 7.6 min., t 1/2 (beta) of 132 +/- 48 min., Vd,ss 72.7 +/- 26.9 L/m2 and Cltot of 0.57 +/- 0.16 L/min/m2.","Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240998/),[l] / [m2],72.7,143929,DB01030,Topotecan
,8240998,Cltot,"Pharmacokinetics showed a t 1/2 (alpha) of 8.1 +/- 7.6 min., t 1/2 (beta) of 132 +/- 48 min., Vd,ss 72.7 +/- 26.9 L/m2 and Cltot of 0.57 +/- 0.16 L/min/m2.","Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240998/),[l] / [m2·min],0.57,143930,DB01030,Topotecan
,10321504,AUCpo,"After oral administration the topotecan lactone AUCpo and F determined for 0.8 and 1.1 mg/m2 per day were 13.6 +/- 5.8 and 25.1 +/- 12.9 ng ml(-1) h and 0.34 +/- 0.14 and 0.34 +/- 0.16, respectively.",Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321504/),[h·ng] / [ml],13.6,145203,DB01030,Topotecan
,10321504,F,"After oral administration the topotecan lactone AUCpo and F determined for 0.8 and 1.1 mg/m2 per day were 13.6 +/- 5.8 and 25.1 +/- 12.9 ng ml(-1) h and 0.34 +/- 0.14 and 0.34 +/- 0.16, respectively.",Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321504/),[h·ng] / [ml],25.1,145204,DB01030,Topotecan
,10321504,F,"After oral administration the topotecan lactone AUCpo and F determined for 0.8 and 1.1 mg/m2 per day were 13.6 +/- 5.8 and 25.1 +/- 12.9 ng ml(-1) h and 0.34 +/- 0.14 and 0.34 +/- 0.16, respectively.",Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321504/),,0.34,145205,DB01030,Topotecan
,10321504,F,"After oral administration the topotecan lactone AUCpo and F determined for 0.8 and 1.1 mg/m2 per day were 13.6 +/- 5.8 and 25.1 +/- 12.9 ng ml(-1) h and 0.34 +/- 0.14 and 0.34 +/- 0.16, respectively.",Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10321504/),,0.34,145206,DB01030,Topotecan
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,13,145395,DB01030,Topotecan
,15313923,IC50,"In Sf9-BCRP vesicles, pantoprazole and omeprazole inhibited MTX transport (IC50 13 microm and 36 microm, respectively).",Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15313923/),μm,36,145396,DB01030,Topotecan
,9815982,maximum tolerated dose,The maximum tolerated dose of 9-AC was determined to be 45 microgram/m2/h.,"A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815982/),[μg] / [h·m2],45,153724,DB01030,Topotecan
,9815982,terminal half-life,"Although significant interpatient variation in plasma 9-AC lactone levels was observed, pooled data were fit to a two-compartment model, with a terminal half-life of 36 h.","A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815982/),h,36,153725,DB01030,Topotecan
,10778953,apparent topotecan clearance,The apparent topotecan clearance demonstrated substantial interpatient variability but remained unchanged within the same patient in the presence [110 +/- 55.6 liters/ h/m2 (mean +/- SD of eight courses)] or absence of pleural and ascitic fluid [118 +/- 31.1 liters/h/m2 (mean +/- SD of seven courses)].,Topotecan lacks third space sequestration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),[l] / [h·m2],110,158377,DB01030,Topotecan
,10778953,apparent topotecan clearance,The apparent topotecan clearance demonstrated substantial interpatient variability but remained unchanged within the same patient in the presence [110 +/- 55.6 liters/ h/m2 (mean +/- SD of eight courses)] or absence of pleural and ascitic fluid [118 +/- 31.1 liters/h/m2 (mean +/- SD of seven courses)].,Topotecan lacks third space sequestration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),[l] / [h·m2],118,158378,DB01030,Topotecan
,10778953,lag time,"Topotecan penetration into pleural and ascitic fluid demonstrated a mean lag time of 1.61 h (range, 1.37-1.86 h), and ratios with plasma concentration increased with time after dosing in all patients.",Topotecan lacks third space sequestration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778953/),h,1.61,158379,DB01030,Topotecan
,11713602,peak secretion,"Biliary secretion of HCPT and M1-M3 reached a peak secretion of 1532+/-124, 75+/-16, 5.8+/-1.6 and 2.1+/-0.5 pmoles/g liver.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver],1532,159260,DB01030,Topotecan
,11713602,peak secretion,"Biliary secretion of HCPT and M1-M3 reached a peak secretion of 1532+/-124, 75+/-16, 5.8+/-1.6 and 2.1+/-0.5 pmoles/g liver.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver],75,159261,DB01030,Topotecan
,11713602,peak secretion,"Biliary secretion of HCPT and M1-M3 reached a peak secretion of 1532+/-124, 75+/-16, 5.8+/-1.6 and 2.1+/-0.5 pmoles/g liver.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver],5.8,159262,DB01030,Topotecan
,11713602,peak secretion,"Biliary secretion of HCPT and M1-M3 reached a peak secretion of 1532+/-124, 75+/-16, 5.8+/-1.6 and 2.1+/-0.5 pmoles/g liver.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver],2.1,159263,DB01030,Topotecan
,11713602,maximum concentrations,"In the perfusate, besides HCPT M1 and M2 but not M3 could be detected (maximum concentrations after about 20 min: 3248+/-210, 16.8+/-2.8 and 1.0+/-0.4 pmoles/g liver.min, respectively).",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver·min],3248,159264,DB01030,Topotecan
,11713602,maximum concentrations,"In the perfusate, besides HCPT M1 and M2 but not M3 could be detected (maximum concentrations after about 20 min: 3248+/-210, 16.8+/-2.8 and 1.0+/-0.4 pmoles/g liver.min, respectively).",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver·min],16.8,159265,DB01030,Topotecan
,11713602,maximum concentrations,"In the perfusate, besides HCPT M1 and M2 but not M3 could be detected (maximum concentrations after about 20 min: 3248+/-210, 16.8+/-2.8 and 1.0+/-0.4 pmoles/g liver.min, respectively).",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),[pmoles] / [g·liver·min],1.0,159266,DB01030,Topotecan
,11713602,cumulative efflux,"The cumulative efflux of HCPT and M1 and M2 into the perfusate was 21.1+/-3.9%, 0.145+/-0.036% and 0.018+/-0.004% of the initial dose, respectively, indicating a preferable non-biliary secretion for HCPT and a predominant biliary elimination for conjugated HCPT biotransformation products.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),%,21.1,159267,DB01030,Topotecan
,11713602,cumulative efflux,"The cumulative efflux of HCPT and M1 and M2 into the perfusate was 21.1+/-3.9%, 0.145+/-0.036% and 0.018+/-0.004% of the initial dose, respectively, indicating a preferable non-biliary secretion for HCPT and a predominant biliary elimination for conjugated HCPT biotransformation products.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),%,0.145,159268,DB01030,Topotecan
,11713602,cumulative efflux,"The cumulative efflux of HCPT and M1 and M2 into the perfusate was 21.1+/-3.9%, 0.145+/-0.036% and 0.018+/-0.004% of the initial dose, respectively, indicating a preferable non-biliary secretion for HCPT and a predominant biliary elimination for conjugated HCPT biotransformation products.",Metabolism and biliary excretion of the novel anticancer agent 10-hydroxycamptothecin in the isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11713602/),%,0.018,159269,DB01030,Topotecan
,8630291,bioavailability,The bioavailability revealed moderate inter-patient variation and was 30% +/- 7.7% (range 21-45%).,Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630291/),%,30,160557,DB01030,Topotecan
,8630291,time to maximum plasma concentration after oral administration (Tmax),The time to maximum plasma concentration after oral administration (Tmax) was 0.78 h (median; range 0.33-2.5).,Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630291/),h,0.78,160558,DB01030,Topotecan
,8630291,plasma clearance,Total i.v. plasma clearance of topotecan was 824 +/- 154 ml min-1 (range 535-1068 ml min(-1)).,Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630291/),[ml] / [min],824,160559,DB01030,Topotecan
,8428353,Peak plasma concentrations,Peak plasma concentrations of topotecan ranged from 0.27 to 0.45 microM.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),μM,0.27 to 0.45,163017,DB01030,Topotecan
,8428353,distribution half-life (t1/2 alpha),Plasma disappearance of the lactone ring was biexponential with a distribution half-life (t1/2 alpha) of 22 +/- 5 min and an elimination half-life (t1/2 beta) of 1.3 +/- 0.1 h.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),min,22,163018,DB01030,Topotecan
,8428353,elimination half-life (t1/2 beta),Plasma disappearance of the lactone ring was biexponential with a distribution half-life (t1/2 alpha) of 22 +/- 5 min and an elimination half-life (t1/2 beta) of 1.3 +/- 0.1 h.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),h,1.3,163019,DB01030,Topotecan
,8428353,Total body clearance,Total body clearance of topotecan was 72.1 +/- 15.8 liters/h/m2.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),[l] / [h·m2],72.1,163020,DB01030,Topotecan
,8428353,volume of distribution at steady state,The volume of distribution at steady state was 88.6 +/- 33.2 liters/m2.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),[l] / [m2],88.6,163021,DB01030,Topotecan
,8428353,Peak CSF concentrations,Peak CSF concentrations of topotecan occurred at 30 min following drug administration and ranged from 0.044 to 0.074 microM.,Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8428353/),μM,0.044 to 0.074,163022,DB01030,Topotecan
,11896112,MTD,"DLTs were typhlitis, diarrhea, and mucositis, and the MTD was 2.4 mg/m(2)/d for 9 days in this group of heavily pretreated children.",Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896112/),mg,2.4,167380,DB01030,Topotecan
,11896112,lactone clearance,"In 33 patients, the median TPT lactone clearance after the first dose was 19.2 L/h/m(2) (range, 9.4 to 45.9 L/h/m(2)) and did not change during the course.",Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896112/),[h·l] / [m(2],19.2,167381,DB01030,Topotecan
,11896112,MTD,The MTD was 2.4 mg/m(2)/d for 9 days.,Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11896112/),[mg] / [d·m(2)],2.4,167382,DB01030,Topotecan
,27551000,response rate,"The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML.","A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27551000/),%,33,169555,DB01030,Topotecan
,27551000,response rate,"The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML.","A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27551000/),%,64,169556,DB01030,Topotecan
,29729631,entrapment efficiency,"Statistical optimization using Box-Behnken design showed that sonication time of primary emulsion for 120 s, drug: polymer ratio of 1:12.65, organic phase: external aqueous phase ratio of 1:2.82 and 0.5% w/v of polyvinyl alcohol in the drug containing phase produced TOPO NPs with a size of 243.2 ± 4 nm and an entrapment efficiency of 60.9 ± 2.2%.","Formulation and optimization of topotecan nanoparticles: In vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29729631/),%,60.9,176778,DB01030,Topotecan
,15961757,area under the plasma concentration-time curve (AUC),"On the basis of topotecan systemic clearance, doses were individualized to attain a single-day topotecan lactone area under the plasma concentration-time curve (AUC) of 80 to 120 ng/mL .",Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961757/),[ng] / [ml],80 to 120,176840,DB01030,Topotecan
,15961757,AUCs,"Target topotecan AUCs were achieved in 92 (72%) of the 127 measurements conducted after pharmacokinetically guided adjustment; the median dosage required to achieve target AUCs was 2.7 mg/m(2) (range, 0.95 to 3.8 mg/m(2)).",Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961757/),[mg] / [m(2],2.7,176841,DB01030,Topotecan
,15961757,response rate,"The response rate was 60% (95% CI, 41% to 77%); there were one complete and 17 partial responses.",Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15961757/),%,60,176842,DB01030,Topotecan
,27169793,MTD,"An MTD of 60 mg/m(2)/day was established for the daily regimen, compared to 90 mg/m(2) for the weekly regimen.","Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169793/),[mg] / [d·m(2)],60,177334,DB01030,Topotecan
,27169793,MTD,"An MTD of 60 mg/m(2)/day was established for the daily regimen, compared to 90 mg/m(2) for the weekly regimen.","Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169793/),[mg] / [m],90,177335,DB01030,Topotecan
,27578324,maximum aqueous humor concentration (Cmax ),"Total topotecan maximum aqueous humor concentration (Cmax ) was 16.1, 69.9 and 287 ng/ml in group A, B and C, respectively.",Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578324/),[ng] / [ml],16.1,186467,DB01030,Topotecan
,27578324,maximum aqueous humor concentration (Cmax ),"Total topotecan maximum aqueous humor concentration (Cmax ) was 16.1, 69.9 and 287 ng/ml in group A, B and C, respectively.",Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578324/),[ng] / [ml],69.9,186468,DB01030,Topotecan
,27578324,maximum aqueous humor concentration (Cmax ),"Total topotecan maximum aqueous humor concentration (Cmax ) was 16.1, 69.9 and 287 ng/ml in group A, B and C, respectively.",Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27578324/),[ng] / [ml],287,186469,DB01030,Topotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB01030,Topotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB01030,Topotecan
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB01030,Topotecan
,8439950,steady-state concentration,The mean steady-state concentration at the MTD was 18.2 +/- 3.7 nmol/liter and the total body clearance was 28.3 +/- 6.5 liters/h/m2.,Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439950/),[nM] / [l],18.2,188024,DB01030,Topotecan
,8439950,total body clearance,The mean steady-state concentration at the MTD was 18.2 +/- 3.7 nmol/liter and the total body clearance was 28.3 +/- 6.5 liters/h/m2.,Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439950/),[l] / [h·m2],28.3,188025,DB01030,Topotecan
,8439950,t1/2 alpha,Elimination was biexponential with a t1/2 alpha of 14.4 +/- 1.8 min and a t1/2 beta of 2.9 +/- 1.1 h.,Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439950/),min,14.4,188026,DB01030,Topotecan
,8439950,t1/2 beta,Elimination was biexponential with a t1/2 alpha of 14.4 +/- 1.8 min and a t1/2 beta of 2.9 +/- 1.1 h.,Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439950/),h,2.9,188027,DB01030,Topotecan
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],75.9,188761,DB01030,Topotecan
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],29.2,188762,DB01030,Topotecan
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],8.5,188763,DB01030,Topotecan
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],9.3,188764,DB01030,Topotecan
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"4,857",188765,DB01030,Topotecan
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"2,808",188766,DB01030,Topotecan
,16328415,area under the plasma concentration-time curve (AUC),"The current study was undertaken to determine the maximum tolerated number of days with 30-minute i.v. infusion of topotecan daily at fixed area under the plasma concentration-time curve (AUC) (i.e., 35 microg/Lxh).",Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328415/),[μg] / [h·l],35,190267,DB01030,Topotecan
,16328415,observed,"The mean (coefficient of variation) observed AUC was 34.6 (21%), and 33.4 (19%) microg/Lxh, for the last day of cycle 1, and of cycle 2, respectively.",Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328415/),[μg] / [h·l],34.6,190268,DB01030,Topotecan
,16328415,AUC,"The mean (coefficient of variation) observed AUC was 34.6 (21%), and 33.4 (19%) microg/Lxh, for the last day of cycle 1, and of cycle 2, respectively.",Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328415/),[μg] / [h·l],34.6,190269,DB01030,Topotecan
,16328415,AUC,"The mean (coefficient of variation) observed AUC was 34.6 (21%), and 33.4 (19%) microg/Lxh, for the last day of cycle 1, and of cycle 2, respectively.",Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16328415/),[μg] / [h·l],33.4,190270,DB01030,Topotecan
,11099328,half-life,Pharmacokinetic analysis showed that DX-8951f had a half-life of 7.15 hours and a clearance rate of 1.65 L/h.m(2).,Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11099328/),h,7.15,191229,DB01030,Topotecan
,11099328,clearance rate,Pharmacokinetic analysis showed that DX-8951f had a half-life of 7.15 hours and a clearance rate of 1.65 L/h.m(2).,Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11099328/),[h·l] / [m(2],1.65,191230,DB01030,Topotecan
,7923128,clearances,"Calculated clearances of topotecan lactone and total drug from the CSF after intraventricular injection were 3.9 and 2.2 ml/h, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),[ml] / [h],3.9,193655,DB01030,Topotecan
,7923128,clearances,"Calculated clearances of topotecan lactone and total drug from the CSF after intraventricular injection were 3.9 and 2.2 ml/h, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),[ml] / [h],2.2,193656,DB01030,Topotecan
,7923128,Clearances,"Clearances of topotecan lactone and total drug from the plasma following a 10-min infusion were 26.3 liters/h/m2 and 17.8 liters/h/m2, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),[l] / [h·m2],26.3,193657,DB01030,Topotecan
,7923128,Clearances,"Clearances of topotecan lactone and total drug from the plasma following a 10-min infusion were 26.3 liters/h/m2 and 17.8 liters/h/m2, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),[l] / [h·m2],17.8,193658,DB01030,Topotecan
,7923128,volume of distribution,"The volume of distribution was 0.77 liters/kg, which represents distribution in a volume approximating total body water.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),[l] / [kg],0.77,193659,DB01030,Topotecan
,7923128,forward,"The forward and reverse rate constants for the lactone-to-hydroxy acid conversion were 1.0 and 0.29 h-1, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),1/[h],1.0,193660,DB01030,Topotecan
,7923128,reverse,"The forward and reverse rate constants for the lactone-to-hydroxy acid conversion were 1.0 and 0.29 h-1, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),1/[h],1.0,193661,DB01030,Topotecan
,7923128,rate constants,"The forward and reverse rate constants for the lactone-to-hydroxy acid conversion were 1.0 and 0.29 h-1, respectively.",A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923128/),1/[h],0.29,193662,DB01030,Topotecan
,24448640,maximum tolerated dosage,The maximum tolerated dosage was determined to be 1.0 mg/m(2).,Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24448640/),[mg] / [m(2],1.0,193815,DB01030,Topotecan
,22028494,MTD,The topotecan MTD in this regimen was 64 mg/m(2) (21.3 mg/m(2)/d).,"Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028494/),[mg] / [m(2],64,195022,DB01030,Topotecan
,22028494,MTD,The topotecan MTD in this regimen was 64 mg/m(2) (21.3 mg/m(2)/d).,"Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22028494/),mg,21.3,195023,DB01030,Topotecan
,16203659,maximum topotecan lactone AUC,"When the administration sequence was changed (topotecan, carboplatin, etoposide), Cycle 1 hematologic toxicity decreased; however, the maximum topotecan lactone AUC of 24-36 ng/mL*hr (median dose 0.82 mg/m2) had significant cumulative hematologic toxicity.",A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),[ng] / [h·ml],24-36,196180,DB01030,Topotecan
,16203659,maximum topotecan lactone AUC,"The number of topotecan doses were reduced from 5 to 3, which resulted in a maximum topotecan lactone AUC of 37 to 53 ng/mL*hr with only 1 of 6 patients having Cycle 1 DLT.",A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),[ng] / [h·ml],37 to 53,196181,DB01030,Topotecan
,16203659,Overall response rate,Overall response rate was 71 percent with median survival of 10.8 months.,A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16203659/),%,71,196182,DB01030,Topotecan
,8083716,Systemic clearance rates,"Systemic clearance rates for lactone and total topotecan were (mean +/- SD) 18.5 +/- 7.0 and 6.5 +/- 2.4 L/h/m2, respectively.",Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083716/),[l] / [h·m2],18.5,198993,DB01030,Topotecan
,8083716,Systemic clearance rates,"Systemic clearance rates for lactone and total topotecan were (mean +/- SD) 18.5 +/- 7.0 and 6.5 +/- 2.4 L/h/m2, respectively.",Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083716/),[l] / [h·m2],6.5,198994,DB01030,Topotecan
,8083716,Urinary recovery,Urinary recovery of total topotecan was (mean +/- SD) 67.5% +/- 25.2% (n = 12 patients).,Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8083716/),%,67.5,198995,DB01030,Topotecan
,7949242,steady-state plasma lactone concentration,A steady-state plasma lactone concentration of 5.5 mg/ml of topotecan was achieved at the phase II recommended dose of 1.6 ng/m2/day as a 3 day continuous infusion.,Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7949242/),[mg] / [ml],5.5,200243,DB01030,Topotecan
,18191511,polydispersity index,The size of both liposomes was around 100 nm with polydispersity index of about 0.1.,The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18191511/),,0.1,201159,DB01030,Topotecan
,8823333,overall response rate,"The overall response rate was 10%, with one complete and three partial responses.",Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823333/),%,10,201388,DB01030,Topotecan
,8823333,response duration,"The median response duration was 7 months (range, 4 to 11).",Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823333/),month,7,201389,DB01030,Topotecan
,8823333,steady-state plasma concentration (Css),"Pharmacokinetic evaluation showed a mean steady-state plasma concentration (Css) of topotecan of 0.62 ng/mL (range, 0.33 to 1.1), with a significant relationship between the Css of topotecan and common cytotoxicity criteria (CTC) grade of leukocytopenia.",Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8823333/),[ng] / [ml],0.62,201390,DB01030,Topotecan
,19010872,terminal half-life,"Delimotecan had a long terminal half-life of 109 h, and relatively high exposures to T-2513 and SN-38 were obtained.",Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19010872/),h,109,202291,DB01030,Topotecan
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,9.1,202531,DB01030,Topotecan
,8275479,mean residence times,"The Cmax for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 +/- 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively.",Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275479/),h,10.0,202532,DB01030,Topotecan
,9533548,urinary recovery,"Topotecan undergoes both renal and hepatic elimination, with topotecan urinary recovery ranging from 60 to 70%.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),%,60 to 70,202905,DB01030,Topotecan
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],62.9,202906,DB01030,Topotecan
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],20.8,202907,DB01030,Topotecan
,9533548,clearance,"Phenytoin coadministration increased lactone and total topotecan clearance from 43.4 +/- 1.9 L/h/m2 to 62.9 +/- 6.4 L/h/m2, and 20.8 +/- 2.8 L/h/m2 to 30.6 +/- 4.1 L/h/m2, respectively (P < 0.05).",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[l] / [h·m2],30.6,202908,DB01030,Topotecan
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],7.5,202909,DB01030,Topotecan
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],16.3,202910,DB01030,Topotecan
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],226.0,202911,DB01030,Topotecan
,9533548,plasma AUC,"Concomitant phenytoin increased the plasma AUC of total N-desmethyl topotecan from 7.5 +/- 0.68 ng/ml x h to 16.3 +/- 0.53 ng/ml x h (P < 0.05) at plasma AUC of total topotecan of 226.0 +/- 5.5 ng/ml x h and 240.9 +/- 39.8 ng/ml x h, respectively.",Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533548/),[ng] / [h·ml],240.9,202912,DB01030,Topotecan
,22010014,area under the curve,Pharmacokinetically guided topotecan dosing (target systemic exposure with area under the curve of 50 to 70 ng/mL/hr) was performed.,Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010014/),[ng] / [h·ml],50 to 70,203054,DB01030,Topotecan
,22010014,overall survival,"In the overall cohort, 3-year event-free and overall survival were 37.8% ± 9.4% and 57.1% ± 9.4%, respectively.",Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010014/),%,57,203055,DB01030,Topotecan
,15737558,plasma t(1/2),The mean plasma t(1/2) was 3.8 +/- 2.3 h for total topotecan and 4.4 +/- 3.9 h for active lactone.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),h,3.8,206347,DB01030,Topotecan
,15737558,plasma t(1/2),The mean plasma t(1/2) was 3.8 +/- 2.3 h for total topotecan and 4.4 +/- 3.9 h for active lactone.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),h,4.4,206348,DB01030,Topotecan
,15737558,peritoneal / plasma AUC ratio,"The area under the curve (AUC) was proportional with dose, R = 0.54, p < 0.05 for total topotecan and the peritoneal / plasma AUC ratio was 46 +/- 30.",A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),,46,206349,DB01030,Topotecan
,15737558,progression-free survival (PFS),Fifteen patients who completed treatment had a median progression-free survival (PFS) of 27 months.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),month,27,206350,DB01030,Topotecan
,15737558,MTD,In this setting the MTD of topotecan is 20 mg/m(2) i.p.,A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15737558/),[mg] / [m],20,206351,DB01030,Topotecan
,9660538,steady-state concentrations of topotecan (C(ss)),"Mean steady-state concentrations of topotecan (C(ss)) in the first course were 0.46+/-0.17 and 0.47+/-0.19 ng/ml after doses of 0.4 and 0.5 mg/m2/day, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),[ng] / [ml],0.46,208865,DB01030,Topotecan
,9660538,steady-state concentrations of topotecan (C(ss)),"Mean steady-state concentrations of topotecan (C(ss)) in the first course were 0.46+/-0.17 and 0.47+/-0.19 ng/ml after doses of 0.4 and 0.5 mg/m2/day, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),[ng] / [ml],0.47,208866,DB01030,Topotecan
,9660538,"C(ss,tot))","Steady-state levels of the total of topotecan and hydroxy acid (C(ss,tot)) were 1.28+/-0.25 (range 0.93-1.58) and 1.57+/-0.19 (range 1.43-1.70) ng/ml at doses of 0.4 and 0.5 mg/m2/day, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),[ng] / [ml],1.28,208867,DB01030,Topotecan
,9660538,"C(ss,tot))","Steady-state levels of the total of topotecan and hydroxy acid (C(ss,tot)) were 1.28+/-0.25 (range 0.93-1.58) and 1.57+/-0.19 (range 1.43-1.70) ng/ml at doses of 0.4 and 0.5 mg/m2/day, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),[ng] / [ml],1.57,208868,DB01030,Topotecan
,9660538,percentage,"The percentage of the administered topotecan dose excreted in the urine within 24 h was 40+/-14 and 1.2+/-1.0% for total topotecan and N-desmethyltopotecan, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),,40,208869,DB01030,Topotecan
,9660538,percentage,"The percentage of the administered topotecan dose excreted in the urine within 24 h was 40+/-14 and 1.2+/-1.0% for total topotecan and N-desmethyltopotecan, respectively.",Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9660538/),,1.2,208870,DB01030,Topotecan
,10071262,maximum-tolerated dose,"After encountering dose-limiting toxicities (DLTs) without G-CSF support, the maximum-tolerated dose was defined as 5 microg/kg of G-CSF subcutaneously starting on day 6.","Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071262/),,5,209304,DB01030,Topotecan
,9533544,complete response,SN-38 systemic exposure associated with the lowest oral dose (25 mg/kg) achieving complete response for HC1 was 942.6 ng/ml x h.,Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9533544/),[ng] / [h·ml],94,210595,DB01030,Topotecan
,8529278,ventricular lactone concentrations,"The median CSF ventricular lactone concentrations, obtained prior to the end of infusion (EOI), were 0.86, 1.4, 0.73, 5.3, and 4.6 ng/ml for patients receiving 0.5, 1.0, 1.25, 5.5, and 7.5 mg/m2 per day, respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),[ng] / [ml],0.86,214214,DB01030,Topotecan
,8529278,ventricular lactone concentrations,"The median CSF ventricular lactone concentrations, obtained prior to the end of infusion (EOI), were 0.86, 1.4, 0.73, 5.3, and 4.6 ng/ml for patients receiving 0.5, 1.0, 1.25, 5.5, and 7.5 mg/m2 per day, respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),[ng] / [ml],1.4,214215,DB01030,Topotecan
,8529278,ventricular lactone concentrations,"The median CSF ventricular lactone concentrations, obtained prior to the end of infusion (EOI), were 0.86, 1.4, 0.73, 5.3, and 4.6 ng/ml for patients receiving 0.5, 1.0, 1.25, 5.5, and 7.5 mg/m2 per day, respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),[ng] / [ml],0.73,214216,DB01030,Topotecan
,8529278,ventricular lactone concentrations,"The median CSF ventricular lactone concentrations, obtained prior to the end of infusion (EOI), were 0.86, 1.4, 0.73, 5.3, and 4.6 ng/ml for patients receiving 0.5, 1.0, 1.25, 5.5, and 7.5 mg/m2 per day, respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),[ng] / [ml],5.3,214217,DB01030,Topotecan
,8529278,ventricular lactone concentrations,"The median CSF ventricular lactone concentrations, obtained prior to the end of infusion (EOI), were 0.86, 1.4, 0.73, 5.3, and 4.6 ng/ml for patients receiving 0.5, 1.0, 1.25, 5.5, and 7.5 mg/m2 per day, respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),[ng] / [ml],4.6,214218,DB01030,Topotecan
,8529278,CSF penetration,"During a 24-h and a 72-h CI, the median CSF penetration of topotecan lactone was 0.29 (range 0.10 to 0.59) and 0.42 (range 0.11 to 0.86), respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),,0.29,214219,DB01030,Topotecan
,8529278,CSF penetration,"During a 24-h and a 72-h CI, the median CSF penetration of topotecan lactone was 0.29 (range 0.10 to 0.59) and 0.42 (range 0.11 to 0.86), respectively.",Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8529278/),,0.42,214220,DB01030,Topotecan
,11551419,AUC,The carboplatin dosage was escalated from an AUC of 4 to 5 to 6 (Calvert formula).,"Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551419/),,4 to 5,215057,DB01030,Topotecan
,11551419,steady-state plasma concentrations,"Mean steady-state plasma concentrations during topotecan infusion ranged from 0.73 to 1.69 ng/ml, and mean etoposide concentrations ranged from 60 to 230 ng/ml.","Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11551419/),[ng] / [ml],0.73 to 1.69,215058,DB01030,Topotecan
,15664349,retention time,"The retention time for the internal standard, acridine, and TPT were 7.4 and 9.0 min, respectively.",High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664349/),min,7.4,218083,DB01030,Topotecan
,15664349,retention time,"The retention time for the internal standard, acridine, and TPT were 7.4 and 9.0 min, respectively.",High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664349/),min,9.0,218084,DB01030,Topotecan
,15664349,recoveries,"The recoveries of free and total TPT from spiked mouse plasma were within 10% of theoretical values (assessed at 1, 20 and 500 ng/ml).",High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15664349/),%,10,218085,DB01030,Topotecan
,8120551,terminal half-life,"Pharmacokinetic studies showed that topotecan plasma concentrations ranged from 1.6 to 7.5 ng/mL during infusions of 1.0 mg/m2/d, and that there was a biphasic plasma distribution with a mean terminal half-life of 2.9 +2- 1.0 hours.",Phase I study of topotecan for pediatric patients with malignant solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8120551/),h,2.9,221173,DB01030,Topotecan
,16501591,MTDs,High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion).,Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16501591/),[mg] / [m2],10.5,222421,DB01030,Topotecan
,16501591,MTDs,High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion).,Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16501591/),[mg] / [m2],22.5,222422,DB01030,Topotecan
,21069334,progression-free survival,A median progression-free survival of 13 months was recorded among ovarian cancer patients who had minimal (6) or no residuum (3) after platinum-based induction; 5 are alive at 4 years.,Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069334/),month,13,225727,DB01030,Topotecan
,21069334,IP/AUC,Topotecan's AUC IP/AUC plasma ratios ranged from 13 to 119.,Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069334/),,13 to 119,225728,DB01030,Topotecan
,21069334,plasma ratios,Topotecan's AUC IP/AUC plasma ratios ranged from 13 to 119.,Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21069334/),,13 to 119,225729,DB01030,Topotecan
,9554590,clearance (CL),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [h·kg],2.1,226844,DB01030,Topotecan
,9554590,volume of distribution at steady state (Vd[ss]),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [kg],1.6,226845,DB01030,Topotecan
,9554590,half-life (t1/2),"9-AC lactone had a clearance (CL) of 2.1 +/- 0.9 l/kg per h, a volume of distribution at steady state (Vd[ss]) of 1.6 +/- 0.7 l/kg and a half-life (t1/2) of 3.2 +/- 0.8 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),h,3.2,226846,DB01030,Topotecan
,9554590,CL,"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [h·kg],3.4,226847,DB01030,Topotecan
,9554590,Vd(ss),"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),[l] / [kg],7.1,226848,DB01030,Topotecan
,9554590,t1/2,"For irinotecan, the CL was 3.4 +/- 0.4 l/kg per h, the Vd(ss) was 7.1 +/- 1.3 l/kg, and the t1/2 was 4.9 +/- 2.2 h.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),h,4.9,226849,DB01030,Topotecan
,9554590,AUC(CSF):AUC(P) ratio,The AUC(CSF):AUC(P) ratio for irinotecan lactone was 14 +/- 3%.,"Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,14,226850,DB01030,Topotecan
<,9554590,AUC(CSF):AUC(P) ratio,The AUC(CSF):AUC(P) ratio for SN-38 lactone was estimated to be < or = 8%.,"Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,8,226851,DB01030,Topotecan
,9554590,AUC(CSF):AUC(P) ratio,"Despite their structural similarity, the CSF penetration of 9-AC and SN-38 is substantially less than that of topotecan which we previously found to have an AUC(CSF):AUC(P) ratio of 32%.","Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9554590/),%,32,226852,DB01030,Topotecan
,14586557,time to tumor progression,The median time to tumor progression was 43 days (95% CI 37-92 days).,"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),d,43,227622,DB01030,Topotecan
,14586557,overall survival,The median overall survival was 117 days (95% CI 90-279 days).,"A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),d,117,227623,DB01030,Topotecan
,14586557,plasma clearance,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),[h·l] / [m(2],2.1,227624,DB01030,Topotecan
,14586557,total volume of distribution,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),[l] / [m(2],20,227625,DB01030,Topotecan
,14586557,terminal elimination half-life,"The average plasma clearance, total volume of distribution, and terminal elimination half-life were 2.1 l/h per m(2), 20 l/m(2) and 9.5 h, respectively.","A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586557/),h,9.5,227626,DB01030,Topotecan
,8186175,AUC,A single point model was selected as optimal: AUC (mumol/L.min) = 499 (min).,Limited sampling models for topotecan pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186175/),min,499,227839,DB01030,Topotecan
,8186175,AUC Tm,"C2h (mumol/L) +0.85 (m2/mg.mumol/L.min).dose(mg/m2), and for topotecan-metabolite (Tm), AUC Tm (mumol/L.min) = 55.1 (min).",Limited sampling models for topotecan pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8186175/),min,55.1,227840,DB01030,Topotecan
,8646800,AUC of the closed-ring form (AUC(closed)),"The mean AUC of the closed-ring form (AUC(closed)) was 8.74 (range 2.3-16.3 microM min per day, and the mean AUC of the ring-opened form (AUC(open)) was 11.5 (range 3.2-46.0) microM min per day (interpatient variability 34-61%).",Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646800/),[min·μM] / [d],8.74,231511,DB01030,Topotecan
,8646800,AUC of the ring-opened form (AUC(open)),"The mean AUC of the closed-ring form (AUC(closed)) was 8.74 (range 2.3-16.3 microM min per day, and the mean AUC of the ring-opened form (AUC(open)) was 11.5 (range 3.2-46.0) microM min per day (interpatient variability 34-61%).",Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646800/),[min·μM] / [d],11.5,231512,DB01030,Topotecan
,27052877,Ka,"A one-compartment model with first-order input and first-order elimination was found to adequately characterize topotecan lactone concentrations with population estimates as [mean (S.E.)]; Ka = 0.61 (0.11) h(-1), apparent volume of distribution (V/F) = 40.2 (7.0) l, and apparent clearance (CL/F) = 40.0 (2.9) l/h.",Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052877/),1/[h],0.61,232660,DB01030,Topotecan
,27052877,apparent volume of distribution (V/F),"A one-compartment model with first-order input and first-order elimination was found to adequately characterize topotecan lactone concentrations with population estimates as [mean (S.E.)]; Ka = 0.61 (0.11) h(-1), apparent volume of distribution (V/F) = 40.2 (7.0) l, and apparent clearance (CL/F) = 40.0 (2.9) l/h.",Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052877/),l,40.2,232661,DB01030,Topotecan
,27052877,apparent clearance (CL/F),"A one-compartment model with first-order input and first-order elimination was found to adequately characterize topotecan lactone concentrations with population estimates as [mean (S.E.)]; Ka = 0.61 (0.11) h(-1), apparent volume of distribution (V/F) = 40.2 (7.0) l, and apparent clearance (CL/F) = 40.0 (2.9) l/h.",Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27052877/),[l] / [h],40.0,232662,DB01030,Topotecan
,21878842,Maximum total topotecan concentration,"Maximum total topotecan concentration in the vitreous (median, range) was significantly higher after OAI compared with POI (131.8 ng/mL [112.9-138.7] vs. 13.6 ng/mL [5.5-15.3], respectively; P < 0.005).",Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878842/),[ng] / [ml],131.8,234061,DB01030,Topotecan
,21878842,Maximum total topotecan concentration,"Maximum total topotecan concentration in the vitreous (median, range) was significantly higher after OAI compared with POI (131.8 ng/mL [112.9-138.7] vs. 13.6 ng/mL [5.5-15.3], respectively; P < 0.005).",Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878842/),[ng] / [ml],13.6,234062,DB01030,Topotecan
,21878842,area under the curve,"Median vitreous exposure calculated as area under the curve for total topotecan attained after OAI was significantly higher than after POI (299.8 ng·hour/mL [247.6-347.2] and 48.9 ng·hour/mL [11.8-63.4], respectively; P < 0.05).",Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878842/),[h·ng] / [ml],299.8,234063,DB01030,Topotecan
,21878842,area under the curve,"Median vitreous exposure calculated as area under the curve for total topotecan attained after OAI was significantly higher than after POI (299.8 ng·hour/mL [247.6-347.2] and 48.9 ng·hour/mL [11.8-63.4], respectively; P < 0.05).",Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21878842/),[h·ng] / [ml],48.9,234064,DB01030,Topotecan
,12659422,CL,Large interindividual variability in pharmacokinetic parameters occurred (CL varied from 10.4 to 23 L/h) while interoccasion variability was limited (6%).,Modeling plasma and saliva topotecan concentration time course using a population approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12659422/),[l] / [h],10.4 to 23,234636,DB01030,Topotecan
,16595064,maximum tolerated dose,"The maximum tolerated dose for docetaxel and topotecan were 60 mg/m(2) on day 1 and 0.75 mg/m(2) days 1 - 5, respectively.",Phase I study of docetaxel and topotecan in patients with advanced malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595064/),mg,60,236696,DB01030,Topotecan
,16595064,area under the curve (AUC),Subjects with grade >or= 3 haematologic toxicity had higher plasma docetaxel or topotecan area under the curve (AUC) (docetaxel 1.03 +/- 0.11 mg-hr/L versus 0.73 +/- 0.13 mg-hr/L; topotecan 65.8 +/- 14.6 mcg-hr/L versus 41.6 +/- 13.9 mcg-hr/L).,Phase I study of docetaxel and topotecan in patients with advanced malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595064/),[mg-hr] / [l],1.03,236697,DB01030,Topotecan
,16595064,area under the curve (AUC),Subjects with grade >or= 3 haematologic toxicity had higher plasma docetaxel or topotecan area under the curve (AUC) (docetaxel 1.03 +/- 0.11 mg-hr/L versus 0.73 +/- 0.13 mg-hr/L; topotecan 65.8 +/- 14.6 mcg-hr/L versus 41.6 +/- 13.9 mcg-hr/L).,Phase I study of docetaxel and topotecan in patients with advanced malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595064/),[mg-hr] / [l],0.73,236698,DB01030,Topotecan
,16595064,area under the curve (AUC),Subjects with grade >or= 3 haematologic toxicity had higher plasma docetaxel or topotecan area under the curve (AUC) (docetaxel 1.03 +/- 0.11 mg-hr/L versus 0.73 +/- 0.13 mg-hr/L; topotecan 65.8 +/- 14.6 mcg-hr/L versus 41.6 +/- 13.9 mcg-hr/L).,Phase I study of docetaxel and topotecan in patients with advanced malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595064/),[mcg-hr] / [l],65.8,236699,DB01030,Topotecan
,16595064,area under the curve (AUC),Subjects with grade >or= 3 haematologic toxicity had higher plasma docetaxel or topotecan area under the curve (AUC) (docetaxel 1.03 +/- 0.11 mg-hr/L versus 0.73 +/- 0.13 mg-hr/L; topotecan 65.8 +/- 14.6 mcg-hr/L versus 41.6 +/- 13.9 mcg-hr/L).,Phase I study of docetaxel and topotecan in patients with advanced malignancies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16595064/),[mcg-hr] / [l],41.6,236700,DB01030,Topotecan
,8118810,plasma steady-state concentrations,"During infusion, mean topotecan plasma steady-state concentrations ranged from 4.7-11.4 nM.",Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118810/),nM,4.7-11.4,240417,DB01030,Topotecan
,8118810,t1/2,Plasma elimination was best fit to a one-compartment model with a mean t1/2 of 3.5 h.,Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118810/),h,3.5,240418,DB01030,Topotecan
,8118810,total body clearance,The mean total body clearance was 388 ml/min/m2.,Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8118810/),[ml] / [m2·min],388,240419,DB01030,Topotecan
,11245909,DS,Results showed that CM dextran from Dextran T-110 (MW 110 kDa) with a DS value of 0.4 is an appropriate drug carrier for T-0128 regarding plasma half-life and passive tumor targeting.,"Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11245909/),,0.4,240838,DB01030,Topotecan
,11350890,plasma C(max),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),[μg] / [ml],16.4,241513,DB01030,Topotecan
,11350890,plasma C(max),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),μM,29.1,241514,DB01030,Topotecan
,11350890,plasma AUC(0--12 h),"Pharmacokinetic analysis revealed a mean Apomine plasma C(max) of 16.4 +/- 9.1 microg/ml (29.1 microM), a mean plasma AUC(0--12 h) of 173.4 +/- 105 microg.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),μg,173.4,241515,DB01030,Topotecan
,11350890,t(1/2,"h/ml (308 microM. h), and a mean t(1/2 (24--192 h)) of 156.2 +/- 42.9 h.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),h,24-,241516,DB01030,Topotecan
,11350890,t(1/2,"h/ml (308 microM. h), and a mean t(1/2 (24--192 h)) of 156.2 +/- 42.9 h.","Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350890/),h,156.2,241517,DB01030,Topotecan
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],32.4,242480,DB01030,Topotecan
,12089223,area under the plasma concentration-time curve (AUC),"After oral topotecan, the mean area under the plasma concentration-time curve (AUC) of total topotecan increased significantly from 32.4 +/- 9.6 microg.h/L without GF120918 to 78.7 +/- 20.6 microg.h/L when GF120918 was coadministered (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[h·μg] / [l],78.7,242481,DB01030,Topotecan
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],4.1,242482,DB01030,Topotecan
,12089223,maximum plasma concentration,The mean maximum plasma concentration of total topotecan increased from 4.1 +/- 1.5 microg/L without GF120918 to 11.5 +/- 2.4 microg/L with GF120918 (P =.008).,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),[μg] / [l],11.5,242483,DB01030,Topotecan
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242484,DB01030,Topotecan
,12089223,apparent bioavailability,"The apparent bioavailability in this cohort increased significantly from 40.0% (range, 32% to 47%) to 97.1% (range, 91% to 120%) (P =.008).",Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242485,DB01030,Topotecan
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,17,242486,DB01030,Topotecan
,12089223,apparent bioavailability,Interpatient variability of the apparent bioavailability was 17% without and 11% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,11,242487,DB01030,Topotecan
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,40.0,242488,DB01030,Topotecan
,12089223,apparent oral bioavailability,The apparent oral bioavailability increased from 40.0% without to 97.1% with GF120918.,Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12089223/),%,97.1,242489,DB01030,Topotecan
,10741709,time to progression,Median time to progression was 12.3 weeks.,Phase II study of oral topotecan in advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741709/),weeks,12.3,242583,DB01030,Topotecan
,10741709,area under the curve,"The mean area under the curve of TPT following 2.3 mg/m2 p.o. was 51.6 ng.h/ml (%SD, 25%).",Phase II study of oral topotecan in advanced non-small cell lung cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741709/),[h·ng] / [ml],51.6,242584,DB01030,Topotecan
,10741709,time to progression,"Although oral TPT at the applied dose and schedule showed modest activity as a single agent, almost one-half of the patients had a stable disease, and median time to progression was 12.3 weeks.",Phase II study of oral topotecan in advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741709/),weeks,12.3,242585,DB01030,Topotecan
,10741709,overall median survival,"The overall median survival was a promising 39.9 weeks, and useful palliation of symptoms was seen.",Phase II study of oral topotecan in advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10741709/),weeks,39.9,242586,DB01030,Topotecan
,23354352,absolute bioavailability,"The mean absolute bioavailability of total topotecan and topotecan in the lactone form was 42.24±12.9% and 47.18±16.9%, respectively, values which illustrate good systemic exposure.",Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354352/),%,42.24,245086,DB01030,Topotecan
,23354352,absolute bioavailability,"The mean absolute bioavailability of total topotecan and topotecan in the lactone form was 42.24±12.9% and 47.18±16.9%, respectively, values which illustrate good systemic exposure.",Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23354352/),%,47.18,245087,DB01030,Topotecan
,18318429,area under the concentration-time curve,"The median (range) topotecan lactone area under the concentration-time curve after the first dose was 85.4 L/hour/m(2) (range, 38.7-229.3 L/hour/m(2)).","Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318429/),[h·l] / [m(2],85.4,246782,DB01030,Topotecan
,15447993,peak plasma concentrations,"Etoposide peak plasma concentrations ranged from 1.9 to 6.9 microg/mL (mean, 3.6 microg/mL).",Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),[μg] / [ml],3.6,250916,DB01030,Topotecan
,15447993,peak plasma concentration,The peak plasma concentration of topotecan was 12.82 +/- 8.55 microg/mL with a plasma half-life of 6.17 +/- 2.75 hours.,Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),[μg] / [ml],12.82,250917,DB01030,Topotecan
,15447993,plasma half-life,The peak plasma concentration of topotecan was 12.82 +/- 8.55 microg/mL with a plasma half-life of 6.17 +/- 2.75 hours.,Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),h,6.17,250918,DB01030,Topotecan
,15447993,overall response rate,"The overall response rate was 38% [complete response, three (14%); partial response, five (24%)].",Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15447993/),%,38,250919,DB01030,Topotecan
,11742479,apparent V(ss),"The apparent V(ss) was 69.9 +/- 25.4 L/m(2), plasma clearance 13.4 +/- 2.5 L/h/m(2) and plasma T1/2 3.7 +/- 1.3 h.",A phase I and pharmacokinetic study of intraperitoneal topotecan. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742479/),[l] / [m(2],69.9,255863,DB01030,Topotecan
,11742479,plasma clearance,"The apparent V(ss) was 69.9 +/- 25.4 L/m(2), plasma clearance 13.4 +/- 2.5 L/h/m(2) and plasma T1/2 3.7 +/- 1.3 h.",A phase I and pharmacokinetic study of intraperitoneal topotecan. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742479/),[h·l] / [m(2],13.4,255864,DB01030,Topotecan
,11742479,plasma T1/2,"The apparent V(ss) was 69.9 +/- 25.4 L/m(2), plasma clearance 13.4 +/- 2.5 L/h/m(2) and plasma T1/2 3.7 +/- 1.3 h.",A phase I and pharmacokinetic study of intraperitoneal topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742479/),h,3.7,255865,DB01030,Topotecan
,11742479,T1/2,Peritoneal total topotecan was cleared from the peritoneal cavity at 0.4 +/- 0.3 L/h.m(2) with a T1/2 = 2.7 +/- 1.7 h.,A phase I and pharmacokinetic study of intraperitoneal topotecan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742479/),h,2.7,255866,DB01030,Topotecan
,11742479,peritoneal/plasma AUC ratio,The mean peritoneal/plasma AUC ratio for total topotecan was 54 +/- 34.,A phase I and pharmacokinetic study of intraperitoneal topotecan. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11742479/),,54,255867,DB01030,Topotecan
,16461424,plasma area under the concentration-time curve [AUC],"We studied children with high-risk medulloblastoma who received pharmacokinetically guided TPT (target plasma area under the concentration-time curve [AUC], 120-160 ng/ml-h) and obtained serial vCSF samples to assess TPT exposure.",Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461424/),[ng] / [ml-h],120-160,257429,DB01030,Topotecan
,16461424,AUC,We simulated TPT vCSF exposure duration at plasma TPT AUC values of 120 to 200 ng/ml-h and determined percentages of studies meeting or exceeding the vCSF exposure duration threshold (EDT) of 1 ng/ml for 8 h.,Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461424/),[ng] / [ml-h],120 to 200,257430,DB01030,Topotecan
,16461424,AUC,"Given a plasma TPT AUC of 120 ng/ml-h, the median percentage of results meeting or exceeding EDT was 78% (95% CI, 61%-100%).",Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461424/),[ng] / [ml-h],120,257431,DB01030,Topotecan
,16461424,AUC,"Further, our results indicate that the TPT vCSF EDT can be achieved in more than 80% of studies targeted to a plasma TPT AUC of 120 ng/ml-h.",Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461424/),[ng] / [ml-h],120,257432,DB01030,Topotecan
,10561322,overall response rate,"One patient with nonmeasurable disease had a PR (by CA-125 criteria) that lasted 6 months, for an overall response rate of 38% in nine of 24 patients (95% CI, 18% to 57%).",Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561322/),%,38,257734,DB01030,Topotecan
,10561322,time to progression,The median time to progression was 26 weeks.,Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561322/),weeks,26,257735,DB01030,Topotecan
,10561322,objective response rate,"The objective response rate of 35% to 38% (95% CI, 15% to 57%) in this small multicenter study is at the upper level for topotecan therapy in previously treated ovarian cancer.",Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561322/),%,35,257736,DB01030,Topotecan
,10561322,objective response rate,"The objective response rate of 35% to 38% (95% CI, 15% to 57%) in this small multicenter study is at the upper level for topotecan therapy in previously treated ovarian cancer.",Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10561322/),%,38,257737,DB01030,Topotecan
,7805183,t1/2(alpha),"The plasma kinetics of topotecan could be described best using an open two-compartment model with t1/2(alpha) and t1/2(beta) of 8.1 (range 0.3 to 40.7) min and 132 (range 49 to 286) min, respectively.",Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7805183/),min,8.1,257789,DB01030,Topotecan
,7805183,t1/2(beta),"The plasma kinetics of topotecan could be described best using an open two-compartment model with t1/2(alpha) and t1/2(beta) of 8.1 (range 0.3 to 40.7) min and 132 (range 49 to 286) min, respectively.",Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7805183/),min,132,257790,DB01030,Topotecan
,7805183,t1/2(formation),"The plasma concentration-time profiles of the metabolite, however, could be described using a one-compartment model with t1/2(formation) of 29.0 (range 5.6-99.5) min and t1/2 (elimination of 123.2 (range 32-265) min, respectively.",Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7805183/),min,29.0,257791,DB01030,Topotecan
,7805183,t1/2 (elimination,"The plasma concentration-time profiles of the metabolite, however, could be described using a one-compartment model with t1/2(formation) of 29.0 (range 5.6-99.5) min and t1/2 (elimination of 123.2 (range 32-265) min, respectively.",Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7805183/),min,123.2,257792,DB01030,Topotecan
,15974453,relative tumor uptake ratios,"Moreover, the liposomal encapsulation changed the biodistribution behavior, and H-Lip and H-PEG dramatically increased the accumulation of TPT in tumor, and the relative tumor uptake ratios were 3.4 and 4.3 compared with free drug, respectively.",In vitro and in vivo studies of different liposomes containing topotecan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15974453/),,3.4,259301,DB01030,Topotecan
,15974453,relative tumor uptake ratios,"Moreover, the liposomal encapsulation changed the biodistribution behavior, and H-Lip and H-PEG dramatically increased the accumulation of TPT in tumor, and the relative tumor uptake ratios were 3.4 and 4.3 compared with free drug, respectively.",In vitro and in vivo studies of different liposomes containing topotecan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15974453/),,4.3,259302,DB01030,Topotecan
,15139512,MTT,"The estimates of MTT and Slp for the three cell populations ranged from 1.89 to 2.18 days and from 0.01 to 0.039 ml/ng, respectively.",Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139512/),d,1.89 to 2.18,261940,DB01030,Topotecan
,15139512,Slp,"The estimates of MTT and Slp for the three cell populations ranged from 1.89 to 2.18 days and from 0.01 to 0.039 ml/ng, respectively.",Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15139512/),[ml] / [ng],0.01 to 0.039,261941,DB01030,Topotecan
,11533095,plasma clearance of unbound cisplatin (CL(free)),"The mean plasma clearance of unbound cisplatin (CL(free)) was 57.1 +/- 14.7 L/h (range, 31.0 to 116 L/h), with an interpatient variability of 25.6%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),[l] / [h],57.1,262601,DB01030,Topotecan
,11533095,BSA,"BSA varied between 1.43 and 2.40 m(2) (mean, 1.86 +/- 0.19 m(2)), with an interpatient variability of 10.4%.",Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11533095/),m(2),1.86,262602,DB01030,Topotecan
,19808951,CL,"Plasma total topotecan concentrations decreased biexponentially, with a mean CL value of 20.6 L/h, V(ss) value of 101 L, and t(1/2) value of 5.0 h.","A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808951/),[l] / [h],20.6,263691,DB01030,Topotecan
,19808951,V(ss),"Plasma total topotecan concentrations decreased biexponentially, with a mean CL value of 20.6 L/h, V(ss) value of 101 L, and t(1/2) value of 5.0 h.","A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808951/),l,101,263692,DB01030,Topotecan
,19808951,t(1/2),"Plasma total topotecan concentrations decreased biexponentially, with a mean CL value of 20.6 L/h, V(ss) value of 101 L, and t(1/2) value of 5.0 h.","A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19808951/),h,5.0,263693,DB01030,Topotecan
>,30102470,payload capacity,"PA, a hydrophobic counterion, increases the hydrophobicity of MET and TPT and facilitates MSNs with exceptionally high payload capacity (>40 and 32 wt%, respectively) and controlled release profile.",Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30102470/),,40,267216,DB01030,Topotecan
>,30102470,payload capacity,"PA, a hydrophobic counterion, increases the hydrophobicity of MET and TPT and facilitates MSNs with exceptionally high payload capacity (>40 and 32 wt%, respectively) and controlled release profile.",Synchronized Ratiometric Codelivery of Metformin and Topotecan through Engineered Nanocarrier Facilitates In Vivo Synergistic Precision Levels at Tumor Site. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30102470/),,32,267217,DB01030,Topotecan
,10424739,Maximal plasma concentrations,Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6+/-4.4 ng ml(-1)) or without food (9.2+/-4.1 ng ml(-1)) (P = 0.130).,Oral topotecan: bioavailablity and effect of food co-administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),[ng] / [ml],10.6,267867,DB01030,Topotecan
,10424739,Maximal plasma concentrations,Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6+/-4.4 ng ml(-1)) or without food (9.2+/-4.1 ng ml(-1)) (P = 0.130).,Oral topotecan: bioavailablity and effect of food co-administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),[ng] / [ml],9.2,267868,DB01030,Topotecan
,10424739,time needed to reach maximal plasma levels,"The time needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8-6.1) compared to fasted conditions (2.0 h, range 1.1-8.1) (P = 0.013).",Oral topotecan: bioavailablity and effect of food co-administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),h,3.1,267869,DB01030,Topotecan
,10424739,time needed to reach maximal plasma levels,"The time needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8-6.1) compared to fasted conditions (2.0 h, range 1.1-8.1) (P = 0.013).",Oral topotecan: bioavailablity and effect of food co-administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),h,2.0,267870,DB01030,Topotecan
,10424739,absolute bioavailability,The absolute bioavailability of topotecan averaged 42+/-13% (90% CI 37-47%).,Oral topotecan: bioavailablity and effect of food co-administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),%,42,267871,DB01030,Topotecan
,10424739,apparent terminal half-life,The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9+/-1.0 h) than after i.v. administration (2.7+/-0.4 h) (P < 0.001).,Oral topotecan: bioavailablity and effect of food co-administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),h,3.9,267872,DB01030,Topotecan
,10424739,apparent terminal half-life,The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9+/-1.0 h) than after i.v. administration (2.7+/-0.4 h) (P < 0.001).,Oral topotecan: bioavailablity and effect of food co-administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424739/),h,2.7,267873,DB01030,Topotecan
,8070027,half-life,"Plasma elimination curves were fit to a one-compartment model, in which the harmonic mean half-life of topotecan was 3.5 h.","Clinical, pharmacokinetic and biological studies of topotecan. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070027/),h,3.5,272594,DB01030,Topotecan
